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Ioanna Tzoulaki, PhD; Ibrahim Karaman, PhD; Claire Boulange, PhD; Dhananjay Vaidya, MBBS, MPH, PhD; Naresh Punjabi, MD, PhD;
Matthew Allison, MD, MPH; David M. Herrington, MD; J. Wouter Jukema, PhD; Frits R. Rosendaal, PhD; Hildo J. Lamb, PhD;
Ko Willems van Dijk, PhD; Philip Greenland, MD; Renee de Mutsert, PhD
Background-—Identifying associations between serum metabolites and visceral adipose tissue (VAT) could provide novel
biomarkers of VAT and insights into the pathogenesis of obesity-related diseases. We aimed to discover and replicate metabolites
reflecting pathways related to VAT.
Methods and Results-—Associations between fasting serum metabolites and VAT area (by computed tomography or magnetic
resonance imaging) were assessed with cross-sectional linear regression of individual-level data from participants in MESA (Multi-
Ethnic Study of Atherosclerosis; discovery, N=1103) and the NEO (Netherlands Epidemiology of Obesity) study (replication,
N=2537). Untargeted 1H nuclear magnetic resonance metabolomics profiling of serum was performed in MESA, and metabolites
were replicated in the NEO study using targeted 1H nuclear magnetic resonance spectroscopy. A total of 30 590 metabolomic
spectral variables were evaluated. After adjustment for age, sex, race/ethnicity, socioeconomic status, smoking, physical activity,
glucose/lipid-lowering medication, and body mass index, 2104 variables representing 24 nonlipid and 49 lipid/lipoprotein subclass
metabolites remained significantly associated with VAT (P=4.8891020–1.169103). These included conventional metabolites,
amino acids, acetylglycoproteins, intermediates of glucose and hepatic metabolism, organic acids, and subclasses of
apolipoproteins, cholesterol, phospholipids, and triglycerides. Metabolites mapped to 31 biochemical pathways, including amino
acid substrate use/metabolism and glycolysis/gluconeogenesis. In the replication cohort, acetylglycoproteins, branched-chain
amino acids, lactate, glutamine (inversely), and atherogenic lipids remained associated with VAT (P=1.9091035–8.469107),
with most associations remaining after additional adjustment for surrogates of VAT (glucose level, waist circumference, and serum
triglycerides), reflecting novel independent associations.
Conclusions-—We identified and replicated a metabolite panel associated with VAT in 2 community-based cohorts. These findings
persisted after adjustment for body mass index and appear to define a metabolic signature of visceral adiposity. ( J Am Heart
Assoc. 2019;8:e010810. DOI: 10.1161/JAHA.118.010810.)
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A lthough obesity is associated with increased risk ofdiabetes mellitus and cardiovascular disease (CVD),
many obese individuals remain free of cardiometabolic
disease.1 One factor that contributes to the heterogeneity
of risk among obese individuals is the amount of visceral
adipose tissue (VAT).2 Excess VAT is associated with insulin
resistance, atherogenic dyslipidemia, and hepatic steatosis3;
and in the long-term, excess VAT has been linked with
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increases in the risk of developing type 2 diabetes mellitus4
and the metabolic syndrome,5 across the spectrum of body
mass index (BMI).
Currently, precise measures of VAT are only obtainable
through assessment with advanced imaging techniques, such
as computed tomography and magnetic resonance imaging
(MRI). Determination of VAT burden and its application to
prevention or treatment of cardiometabolic outcomes are,
therefore, not currently practical for routine clinical use.
Anthropometric approximations, like waist circumference, are
not sufficient to assess risk associated with VAT,6 and specific
blood-based metabolic markers reflecting pathways related to
VAT are lacking.
The development of high-throughput metabolomics profil-
ing has made it feasible to acquire profiles of a whole
organism’s metabolic status.7 The metabolome profile can
provide a high-resolution and reproducible phenotypic signa-
ture of complex disease states, such as type 2 diabetes
mellitus,8 and may offer useful biologic information that can
help with understanding molecular pathways in disease. At
present, there are limited data on the relationship between
metabolite profiles and variation in body fat distribution,
especially with VAT. Studies to date have been composed of
relatively small sample sizes,9,10 a finite number of targeted
metabolites,11 or histological samples of adipose tissue
alone.12 Targeting blood-based metabolites from sufficiently
large numbers of people may yield more robust and
reproducible results from samples that are more easily
obtained in clinical practice. Therefore, we aimed to use data
from 2 large independent cohorts, MESA (Multi-Ethnic Study
of Atherosclerosis) and the NEO (Netherlands Epidemiology of
Obesity) study, to discover and replicate metabolites reflect-
ing various pathways related to visceral fat; and we
performed a mendelian randomization analysis to explore
the potential causal effects of atherogenic dyslipidemia on
VAT deposition.
Methods
The data that support the findings of this study are available
from the corresponding author on reasonable request.
Study Population and Variable Definitions
Multi-Ethnic Study of Atherosclerosis
The overall design of MESA has been described previously.13
Briefly, MESA consists of 6814 men and women, aged 45 to
84 years, who were free of clinical CVD, of different
ethnicities (white, black, Chinese American, and Hispanic)
and enrolled from 6 different sites in the United States.
Clinical CVD was defined as history of myocardial infarction,
angina pectoris, prior revascularization, heart failure, atrial
fibrillation, stroke, or peripheral arterial disease at the time of
enrollment. Baseline medical history, anthropometric mea-
surements, and laboratory data for the present study were
taken from the first examination of MESA cohort (July 2000 to
August 2002), as previously described.14 Education level and
yearly income were determined from a self-reported ques-
tionnaire. Physical activity was derived using a self-reported
frequency and type of leisure time physical activity and a
standard conversion for metabolic equivalence units.15 Fast-
ing serum samples from 3955 participants randomly selected
were collected at the baseline visit to generate untargeted
metabolomics profiles in a subset of MESA participants as
part of the Development of Combinatorial Biomarkers for
Subclinical Atherosclerosis initiative, a collaboration between
MESA investigators and scientists at Imperial College London,
as described below. At examinations 2 or 3, a random subset
of 1970 MESA participants underwent abdominal computed
tomography scans for aortic calcium that were subsequently
used for quantifying visceral fat area: visit 2, n=756; visit 3,
n=1172. For the purposes of the current study, we included
1103 participants with completed assessments of metabo-
lomics and visceral fat. The median (interquartile range) time
between metabolomics and VAT assessments was 3.2 (3.0–
3.4) years.
The NEO study
The NEO study is a population-based, prospective cohort
study, including 6671 individuals aged 45 to 65 years, with an
oversampling of individuals with overweight or obesity.16
Between September 2008 and 2012, men and women living
in the greater area of Leiden (in the West of the Netherlands)
were invited to participate if they were aged between 45 and
65 years and had a self-reported BMI of ≥27 kg/m2. In
Clinical Perspective
What Is New?
• We identified and validated a metabolite signature associ-
ated with visceral adipose tissue from a single fasting blood
sample in 2 large epidemiological cohort studies.
What Are the Clinical Implications?
• These findings provide insight into potential mechanisms
underpinning visceral adipose tissue metabolism distinct
from generalized obesity defined by the body mass index.
• Blood-based metabolic profiling of visceral adipose tissue
using a limited set of important metabolites may address
the implementation gap between recognizing the role of
visceral adiposity in cardiometabolic disease and actually
assessing it clinically.
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addition, all inhabitants, aged between 45 and 65 years, from
one municipality (Leiderdorp) were invited to participate,
irrespective of their BMI, allowing for a reference distribution
of BMI. To correctly represent associations in the Dutch
general population, adjustments for this oversampling have
been made in the analyses17 by weighting individuals toward
the BMI distribution of participants from the Leiderdorp
municipality, whose BMI distribution was similar to the BMI
distribution of the general Dutch population. Consequently,
the results of the analyses in the NEO study apply to a
population-based study without oversampling of individuals
with a BMI ≥27 kg/m2.
Participants were invited to a baseline visit at the NEO
study center after an overnight fast. Before this study visit,
participants completed a general questionnaire at home to
report demographic, lifestyle, and clinical information. At
the baseline visit, an extensive physical examination was
performed, including blood sampling. A high-throughput
proton nuclear magnetic resonance (NMR) metabolomics
platform (Nightingale Health Ltd, Helsinki, Finland) was used
to quantify 224 lipid and metabolite measures in all
participants, as described below. VAT area was quantified
using MRI in 2580 participants who were randomly selected
from those without contraindications for MRI. After exclusion
of missing data (failed MRI, n=11; failed blood sampling,
n=33), 2536 participants were analyzed. Of these partici-
pants, analysis or annotation of separate metabolites failed
in a median of 0.26% (interquartile range, 0.03%–3.49%),
which were not imputed in the statistical analyses. Protocols
were approved by the Institutional Review Board at each
participating institution for MESA and by the Medical Ethical
Committee of the Leiden University Medical Center for the
NEO study. All participants provided written informed
consent.
Metabolomics Measurements
In MESA (the discovery cohort), untargeted 1H NMR analysis
of serum samples obtained at the baseline examination was
performed using a method previously described.18 MESA
samples used in the current study were analyzed in 2 phases
as part of the European Union–funded Development of
Combinatorial Biomarkers for Subclinical Atherosclerosis
project. Details about the preparation of samples, including
quality controls, NMR data acquisition, and NMR data
processing, are described in Data S1. The specific NMR data
sets used in the current study include the following: (1)
standard 1-dimensional NMR spectrum showing resonances
from all proton-containing molecules in the sample, including
broad, largely undefined bands from serum proteins, sharper
and well-defined bands from serum lipoproteins (with some
classification into their main groups), and sharp peaks from a
range of small-molecule metabolites, such as amino acids,
simple carbohydrates, organic acids, organic bases, and
several osmolytes; (2) Carr-Purcell-Meiboom-Gill spectrum
that attenuates the peaks from the macromolecules and
allows better definition of the small molecules; and (3)
quantification of lipoprotein subclasses obtained from decon-
volution of the methyl peak near d0.89 using a Bruker (Bruker
Biospin, Rheinstetten, Germany) procedure adapted from the
method of Petersen et al.19 Bruker NMR measurements
included total high-density lipoprotein (HDL), low-density
lipoprotein (LDL), triglycerides, and cholesterol as well as
analysis of 105 lipoprotein subclasses, including different
chemical components of intermediate-density lipoprotein
(density, 1.006–1.019 kg/L), very-LDL (VLDL; density,
0.950–1.006 kg/L), LDL (density, 1.09–1.63 kg/L), and
HDL (density, 1.063–1.210 kg/L). The LDL subfraction was
separated into 6 density classes (LDL-1, 1.019–1.031 kg/L;
LDL-2, 1.031–1.034 kg/L; LDL-3, 1.034–1.037 kg/L; LDL-4,
1.037–1.040 kg/L; LDL-5, 1.040–1.044 kg/L; and LDL-6,
1.044–1.063 kg/L), and the HDL subfraction was separated
into 4 density classes (HDL-1, 1.063–1.100 kg/L; HDL-2,
1.100–1.125 kg/L; HDL-3, 1.125–1.175 kg/L; and HDL-4,
1.175–1.210 kg/L). These specific NMR spectra have been
previously tested for quality control, harmonization, and
alignment.20
In the NEO study (the replication cohort), targeted
metabolomics were measured using a high-throughput proton
NMR metabolomics platform (Nightingale Health Ltd) to
quantify 224 lipid and metabolite measures in all participants.
The NMR spectroscopy was conducted at the Medical
Research Council Integrative Epidemiology Unit at the
University of Bristol (Bristol, UK) and processed by Nightin-
gale’s biomarker quantification algorithms (version 2014).
This method provides quantification of lipoprotein subclass
profiling with lipid concentrations within 14 lipoprotein
subclasses. The 14 subclass sizes were defined as follows:
extremely large VLDL with particle diameters from 75 nm
upwards and a possible contribution of chylomicrons, 5 VLDL
subclasses (average particle diameters, 64.0, 53.6, 44.5,
36.8, and 31.3 nm), intermediate-density lipoprotein (average
particle diameter, 28.6 nm), 3 LDL subclasses (average
particle diameters, 25.5, 23.0, and 18.7 nm), and 4 HDL
subclasses (average particle diameters, 14.3, 12.1, 10.9, and
8.7 nm). Within the lipoprotein subclasses, the following
components were quantified: total cholesterol, total lipids,
phospholipids, free cholesterol, cholesteryl esters, and triglyc-
erides. The mean size for VLDL, LDL, and HDL particles was
calculated by weighting the corresponding subclass diameters
with their particle concentrations. Furthermore, 58 metabolic
measures were determined that belong to classes of
apolipoproteins, cholesterol, fatty acids, glycerides, phospho-
lipids, amino acids, fluid balance, glycolysis-related
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metabolites, inflammation, and ketone bodies. Details of the
experimentation and applications of the NMR metabolomics
platform have been described previously,21 as well as CVs
(coefficients of variation) for metabolic biomarkers.22,23 A full
list of the measured biomarkers in the NEO study is included
in Table S1.
Body Fat and VAT Measurements
In MESA, weight and height were measured using a balance-
beam scale and stadiometer, respectively, and used to
calculate BMI as weight (in kilograms) divided by height (in
meters) squared. Waist circumference was measured at the
minimum abdominal girth using a steel measuring tape of
standard 4-ounce tension in centimeters. Electron-beam or
multidetector computed tomography scans of the abdomen,
obtained to measure aortic calcification, were used to measure
fat and lean area in the abdomen, as previously described.5
Briefly, visceral fat was defined as the fat enclosed by the
visceral cavity, and fat tissue was identified as being between
190 and 30 Hounsfield units. Within the area of interest,
the density value was assigned to each pixel using the MIPAV
4.1.2 software (National Institutes of Health, Bethesda, MD) as
fat or lean tissue. Six transverse cross-sectional slices were
analyzed (2 at L2–3, 2 at L3–4, and 2 at L4–5), and visceral fat
area (cm2) was calculated as the average of the sum of visceral
fat over all 6 available slices. Interreader and intrareader
reliability for visceral fat area was 0.99 for all measures.
In the NEO study, body weight was assessed by the Tanita
bioimpedance balance (TBF-310; Tanita International Division,
UK) without shoes, and 1 kg was subtracted from the body
weight. Waist circumference was measured midway between
the border of the lower costal margin and the iliac crest.
Abdominal visceral fat was quantified by a turbo spin echo
imaging protocol using MRI. Imaging was performed on a 1.5-
T MR system (Philips Medical Systems, Best, the Nether-
lands). At the level of the fifth lumbar vertebra, 3 transverse
images, each with a slice thickness of 10 mm, were obtained
during a breath hold. Visceral fat area was quantified by
converting the number of pixels to square centimeters for all
3 slides, and the mean area of the 3 slides was used in the
analyses. Earlier studies have shown that such cross-sectional
images are highly correlated to total volumes (correlation
coefficients, 0.8) and can, therefore, validly represent
VAT.24
Statistical Analysis
Baseline characteristics of the study populations are pre-
sented as median (interquartile range) or proportion (percent-
age), as appropriate. Multivariable linear regression models
were constructed to assess the association of metabolites
with VAT for all NMR experiments. To allow for comparisons,
metabolites were logarithmically transformed and standard-
ized to a mean of 0 and an SD of 1. VAT was confirmed to be
normally distributed. Linear regression modeling was per-
formed, with the metabolite as the exposure variable and
mean VAT area as the outcome variable, on the basis of a
hypothesis-free design because the biological features of
metabolomics and VAT may be bidirectional (ie, metabolites
may influence VAT accumulation/function, and/or VAT accu-
mulation may influence downstream metabolic processes).
Furthermore, to uncover potential causal pathways to visceral
fat accumulation, we also performed mendelian randomization
analyses with the replicated metabolites, where possible (see
method below). Models were adjusted for age, sex, race/
ethnicity, socioeconomic status, smoking, physical activity,
glucose and lipid-lowering medication use, and BMI to
investigate to what extent the associations were specific for
VAT and not merely overall body mass. Given the hypothesis-
free design and the large number of comparisons, we adjusted
for multiple testing using a predefined false-discovery rate
threshold of 1% for the primary analysis. Given known
differences in body fat distribution by sex and race/ethnicity,
secondary analyses were performed, stratified by these
variables. We also performed targeted pathway analysis using
Metaboanalyst (http://www.metaboanalyst.ca), a web-based
tool for metabolomics analysis, and interpretation that uses
the Kyoto Encyclopedia of Genes and Genomes and Small
Molecule Pathway databases to perform overrepresentation,
pathway enrichment, and pathway topological analyses (ex-
plained in Data S1). They were used to determine the overall
associations of our metabolite set that map to particular
pathways related to VAT and assess whether the metabolites
are critical connectors within the pathways’ network
structure.25
Next, we used the NEO study as a separate cohort to
replicate our findings with the same statistical analysis
strategy on a targeted metabolomics platform. All analyses
in the NEO study were weighted toward the BMI distribution
of the general population. A predefined false-discovery rate
threshold of 1% was also used for this analysis. Using the
replicated metabolites, to identify novel VAT-associated
metabolites beyond known correlates, we additionally sequen-
tially adjusted for the following: (1) fasting glucose concen-
trations and waist circumference; and (2) plasma triglyceride
concentrations, to investigate if and what metabolites
remained after adjustment for additional modifiers of meta-
bolic disease and indirect surrogate markers for VAT (eg,
“hypertriglyceridemic waist”).26 Finally, to better understand
the potential directionality of the association between lipid-
based metabolites and VAT (ie, does dyslipidemia influence
VAT deposition), we estimated the potential causal effects of
overall measures of HDL cholesterol (HDL-C), LDL cholesterol,
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and triglycerides on VAT volume by performing 2-sample
mendelian randomization analyses using genetic instruments
linked to blood lipid levels and combining the summary
statistics of large genome-wide meta-analyses on blood lipid
levels and VAT (explained in Data S1). Statistical analyses
were performed using SAS software, version 9.4 (SAS
Corporation, Cary, NC), and Stata Statistical Software, version
14.0 (Statacorp, College Station, TX).
Results
Characteristics of the discovery and replication study cohorts
are presented in Table 1. Both cohorts were primarily middle
aged, with 50% women. MESA cohort was racially/ethnically
diverse, with 60% nonwhite participants, compared with the
NEO study cohort, which was predominantly white. The
median BMIs, waist circumferences, and VAT areas for women
and men were modestly higher in MESA than in the NEO
study, generally reflecting known demographic and anthropo-
metric differences between the United States and the
Netherlands.
Metabolite Profiling in MESA
In MESA discovery cohort, 30 590 metabolomic spectral
variables were evaluated in untargeted metabolomics analy-
ses using NMR. After multivariable adjustment for age, sex,
race/ethnicity, socioeconomic status, smoking, physical
activity, glucose and lipid-lowering medication use, and BMI,
2104 spectral variables representing 24 nonlipid (Table 2)
and 49 lipid/lipoprotein subclass metabolites (Table 3)
remained statistically significantly associated with VAT
(P=4.8891020–1.169103). These included conventional
clinical metabolites (eg, creatinine), amino acids and their by-
products (eg, leucine, isoleucine, glutamine [inversely associ-
ated], valine, and proline), acetylglycoproteins and mannose,
intermediates of glucose and hepatic metabolism (eg,
glycerol, glucose, and choline), organic acids (eg, lactate),
subclasses of very-low-density, low-density, intermediate-
density, and high-density apolipoproteins, cholesterol, phos-
pholipids, and triglycerides. In general, among the lipid-based
metabolites, HDL-related metabolites were inversely associ-
ated with VAT. Conversely, intermediate-density lipoprotein
and VLDL particles were almost uniformly positively associ-
ated with VAT. Metabolite profiles were generally consistent
between men and women and between white and nonwhite
participants in stratified analyses (Figures S1 and S2).
Pathway analyses were performed using overrepresenta-
tion, pathway enrichment, and pathway topological analysis
methods for the nonlipid metabolites. Thirty-one distinct
biochemical pathways were identified, mapping to the
metabolite set significantly associated with VAT (Figure 1).
The pathways with the strongest associations with visceral
adiposity (based on P values derived from pathway enrich-
ment analyses reflecting the overall association of the
metabolite set) included those using amino acids as sub-
strates for biosynthetic processes, such as aminoacyl-tRNA
biosynthesis (P=3.3991010) and branched-chain amino acid
degradation (P=1.309104). Other pathways included meta-
bolism of other amino acids and glycolysis/gluconeogenesis.
A full list of the metabolic pathways associated with visceral
adiposity and centrality/impact of the metabolites on each
specific pathway is given in Table S2.
Replication Analysis: The NEO Study
To replicate our findings from MESA in a different
epidemiological cohort, we repeated the analyses with the
metabolites that were significantly associated with VAT in
the discovery cohort by using the targeted Nightingale
metabolomics platform in the NEO study cohort. In this
analysis, 6 of the nonlipid (Table 2) and 34 of the lipid/
lipoprotein subclass metabolites (Table 3) were replicated
and retained statistical significance in the NEO study using
a prespecified false-discovery rate 1% threshold. The b
coefficients (reflecting the magnitude of association
between metabolites and VAT) were highly correlated
between MESA and the NEO study (R2=0.68, Figure 2).
Unadjusted correlations between adiposity variables and
replicated metabolites in both MESA and the NEO study are
reported in Table S3. Similar patterns for metabolite-VAT
associations in sex- and race/ethnicity-stratified analyses
were seen in the replication cohort as in the discovery
cohort (Figures S1 and S2).
Among the replicated metabolites (selecting HDL-C, VLDL
cholesterol, and serum triglycerides to represent the broad
categories of related lipids/lipoproteins associated with VAT),
we performed sequential adjustment for fasting glucose
concentrations and waist circumference and found the
associations between the selected replicated metabolites
and VAT were slightly weaker but retained statistical signif-
icance (Figure 3). After further adjustment for plasma triglyc-
eride concentrations (accounting for hypertriglyceridemic
waist), acetylglycoproteins, branched-chain amino acids
(isoleucine, leucine, and valine), glutamine (inversely), and
serum triglycerides remained significantly associated with
VAT (nominal P<0.05 for all, Figure 3).
Mendelian Randomization Study
Two-sample mendelian randomization analyses using genetic
instruments for blood lipid levels were performed by com-
bining the summary statistics of large-scale genome-wide
DOI: 10.1161/JAHA.118.010810 Journal of the American Heart Association 5
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Table 1. Baseline Characteristics of the Study Populations
Clinical Characteristics MESA (n=1103) NEO Study (n=2536)
Demographics
Age, y 63.0 (54.0–70.0) 56.0 (51.0–61.0)
Men, % 51.6 47.5
Race/ethnicity, %
White 39.8 95.9
Black 17.6 . . .
Hispanic 27.9 . . .
Chinese 14.7 . . .
Other . . . 4.1
Education level, %
Low (some or graduated high school) 35.5 53.7
High (vocational school, university, and postgraduate) 64.5 46.3
Income, $/y, %
0–34 999 43.9 N/A
35 000–99 999 39.8 N/A
≥100 000 16.4 N/A
Medical history
Hypertension, % 48.5 19.7
Diabetes mellitus, % 11.4 3.3
Dyslipidemia, % 43.9 42.5
Metabolic syndrome, % 34.5 23.7
Current smoker, % 14.1 14.4
Moderate and vigorous physical activity, MET9min/wk 4001.3 (2032.5–7260.0) 2850.0 (1597.5–4905.0)
Systolic BP, mm Hg 124.0 (111.0–141.0) 129.0 (118.0–141.0)
Diastolic BP, mm Hg 72.0 (65.0–79.0) 83.0 (76.0–90.0)
BP ≥130/85 mm Hg, % 36.0 56.0
Triglycerides, mg/dL 119.0 (79.0–175.0) 90.3 (64.6–131.9)
Triglycerides ≥150 mg/dL, % 35.1 19.0
HDL-C, mg/dL 48.0 (40.0–59.0) 57.9 (47.5–71.4)
HDL-C <40 mg/dL (men) or <50 mg/dL (women), % 35.8 15.4
Fasting glucose, mg/dL 91.0 (84.0–99.0) 95.3 (89.7–102.5)
Fasting glucose ≥100 mg/dL, % 24.9 32.3
Body composition
BMI, kg/m2 Women: 27.3 (24.4–31.3) Women: 24.9 (22.0–27.5)
Men: 27.2 (24.4–30.1) Men: 26.3 (24.2–28.5)
Waist circumference, cm Women: 96.0 (85.8–105.1) Women: 84.0 (77.0–94.0)
Men: 97.5 (90.6–106.3) Men: 97.0 (91.0–104.0)
Waist circumference ≥102 cm (men) or ≥88 cm (women), % Women: 70.0 Women: 38.0
Men: 36.4 Men: 32.6
VAT area, cm2 Women: 122.4 (82.1–183.0) Women: 56.8 (36.6–89.0)
Men: 191.6 (128.0–248.3) Men: 105.6 (75.1–144.2)
Data are presented as median (interquartile range) or proportion (percentage), as appropriate. Results from the NEO study are based on analyses weighted toward the BMI distribution of the
general population. Number of missing values per variable in the NEO study: ethnicity, 4; education, 26; hypertension, 6; diabetes mellitus, 7; metabolic syndrome, 7; smoking, 3; physical
activity, 11; diastolic BP, 1; triglycerides, 6; HDL-C, 6; and fasting glucose, 9 (no missing values for other variables). BMI indicates body mass index; BP, blood pressure; HDL-C, high-density
lipoprotein cholesterol; MESA, Multi-Ethnic Study of Atherosclerosis; MET, metabolic equivalent; N/A, not applicable; NEO, Netherlands Epidemiology in Obesity; VAT, visceral adipose tissue.
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meta-analyses on blood lipid levels and VAT. Data on both
the instrument-exposure (blood lipid levels) and instrument-
outcome (VAT volume) associations were available for
208 instruments (HDL-C, n=83; LDL cholesterol, n=72;
triglycerides, n=53; with 9 serving as instruments for multiple
traits), after harmonization. As shown in Figure S3, we did not
find evidence for a causal effect of overall measures of HDL-C,
LDL cholesterol, and triglyceride blood levels on VAT volume
Table 2. Associations Between Nonlipid Metabolites and VAT
MESA NEO Study
Metabolite Effect Estimate b (95% CI) Nominal P Value Metabolite Effect Estimate b (95% CI) Nominal P Value
1-Dimensional NMR
Acetylglycoproteins 14.50 (10.87 to 18.13) 1.14E-14 Acetylglycoproteins 11.70 (9.86 to 13.54) 1.58E-34*
Choline 15.54 (19.42 to 11.66) 9.52E-15   
Creatinine 12.88 (9.30 to 16.45) 2.97E-12 Creatinine 1.21 (0.75 to 3.16) 2.25E-01
Glycerol 8.43 (4.65 to 12.20) 1.33E-05   
Glyceryl groups of lipids 13.83 (10.29 to 17.36) 4.15E-14   
Lactate 13.73 (10.14 to 17.32) 1.38E-13 Lactate 4.75 (2.86 to 6.63) 8.46E-07*
Mannose 15.92 (12.33 to 19.52) 1.49E-17   
Myoinositol 7.96 (4.24 to 11.69) 3.05E-05   
Proline 12.90 (9.21 to 16.59) 1.26E-11   
Carr-Purcell-Meiboom-Gill echo acquisition
2-Ketoisovalerate 3.35 (2.24 to 4.46) 4.73E-09   
Acetylglycoproteins 9.22 (6.81 to 11.63) 1.41E-13 Acetylglycoproteins 11.70 (9.86 to 13.54) 1.58E-34*
Alanine 3.50 (4.68 to 2.33) 5.98E-09   
Albumin 1.88 (2.40 to 1.35) 5.98E-12 Albumin 0.02 (1.80 to 1.76) 9.84E-01
a-Glucose 8.34 (11.40 to 5.27) 1.19E-07   
Arginine 1.01 (0.59 to 1.43) 3.25E-06   
b-Glucose 3.29 (4.47 to 2.11) 5.99E-08   
Choline 6.45 (8.56 to 4.34) 3.00E-09   
Citrate 0.30 (0.47 to 0.14) 2.79E-04   
Creatinine 2.99 (2.19 to 3.78) 3.74E-13 Creatinine 1.21 (0.75 to 3.16) 2.25E-01
Ornithine 1.62 (2.41 to 0.84) 5.64E-05   
Glutamate 0.33 (0.14 to 0.51) 5.04E-04   
Glutamine 1.63 (2.24 to 1.03) 1.42E-07 Glutamine 3.09 (5.05 to 1.13) 2.01E-03*
Glyceryl groups of lipids 2.02 (1.54 to 2.50) 4.18E-16   
Isoleucine 2.50 (1.88 to 3.12) 5.25E-15 Isoleucine 13.22 (11.16 to 15.28) 3.78E-35*
Lactate 6.44 (4.81 to 8.07) 2.44E-14 Lactate 4.75 (2.86 to 6.63) 8.46E-07*
Leucine 3.65 (2.50 to 4.79) 7.03E-10 Leucine 12.58 (10.36 to 14.80) 5.23E-28*
Lysine 8.96 (10.94 to 6.98) 3.25E-18   
Mannose 11.42 (9.02 to 13.81) 4.88E-20   
Proline 5.54 (4.12 to 6.96) 5.47E-14   
Pyroglutamate 1.05 (1.36 to 0.73) 1.15E-10   
Valine 3.05 (1.95 to 4.15) 6.55E-08 Valine 6.89 (4.68 to 9.10) 1.07E-09*
Model adjusted for age, sex, race/ethnicity, socioeconomic status, smoking, physical activity, glucose and lipid-lowering medication use, and body mass index. Effect estimate b
represents the difference in VAT area (in cm2) per 1-SD in metabolite intensity (relative units). MESA indicates Multi-Ethnic Study of Atherosclerosis; NEO, Netherlands Epidemiology in
Obesity; NMR, nuclear magnetic resonance; VAT, visceral adipose tissue.
*Metabolites that were significant in the NEO study data set after false-discovery rate correction.
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Table 3. Associations Between Lipid Metabolites and VAT
MESA NEO Study
Metabolite Effect Estimate b (95% CI)
Nominal
P Value Metabolite Effect Estimate b (95% CI)
Nominal P
Value
HDL cholesterol 11.00 (14.74 to
7.25)
1.14E-08 HDL cholesterol 8.11 (10.21 to 6.00) 5.67E-14*
HDL free cholesterol 13.21 (17.15 to
9.27)
7.81E-11   
HDL phospholipids 11.50 (15.50 to
7.50)
2.22E-08   
Total plasma apolipoprotein-A1 7.59 (11.36 to 3.81) 8.84E-05 Total plasma apolipoprotein-A1 2.94 (5.04 to 0.84) 6.09E-03*
Extralarge HDL apolipoprotein-
A1
10.92 (14.75 to
7.10)
2.82E-08   
Extralarge HDL cholesterol 10.72 (14.56 to
6.89)
5.47E-08 Extralarge HDL cholesterol 7.52 (9.61 to 5.44) 1.99E-12*
Extralarge HDL free cholesterol 12.88 (16.61 to
9.15)
2.18E-11 Extralarge HDL free cholesterol 8.24 (10.34 to 6.13) 2.49E-14*
Extralarge HDL phospholipids 12.78 (16.92 to
8.63)
2.12E-09 Extralarge HDL phospholipids 10.66 (12.83 to
8.49)
1.65E-21*
Large HDL apolipoprotein-A1 8.90 (13.38 to 4.41) 1.07E-04   
Large HDL cholesterol 10.68 (14.48 to
6.89)
4.33E-08 Large HDL cholesterol 10.99 (13.07 to
8.92)
8.21E-25*
Large HDL free cholesterol 12.72 (16.66 to
8.78)
3.76E-10 Large HDL free cholesterol 10.98 (13.00 to
8.95)
9.22E-26*
Large HDL phospholipids 10.90 (14.80 to
6.99)
5.66E-08 Large HDL phospholipids 9.52 (11.67 to 7.37) 7.09E-18*
Medium HDL cholesterol 9.15 (12.95 to 5.35) 2.70E-06 Medium HDL cholesterol 3.58 (5.63 to 1.54) 5.92E-04*
Medium HDL free cholesterol 9.83 (14.01 to 5.65) 4.56E-06 Medium HDL free cholesterol 3.52 (5.61 to 1.44) 9.37E-04*
Medium HDL phospholipids 7.88 (11.78 to 3.97) 8.33E-05 Medium HDL phospholipids 1.61 (3.68 to 0.46) 1.27E-01
Medium HDL triglycerides 6.44 (2.56 to 10.31) 1.16E-03 Medium HDL triglycerides 8.65 (6.37 to 10.92) 1.26E-13*
Small HDL triglycerides 11.31 (7.78 to 14.84) 4.87E-10 Small HDL triglycerides 10.65 (8.91 to 12.39) 2.31E-32*
IDL apolipoprotein-B 7.22 (3.36 to 11.08) 2.63E-04   
IDL cholesterol 7.03 (3.27 to 10.80) 2.68E-04 IDL cholesterol 2.36 (0.26 to 4.46) 2.79E-02
IDL free cholesterol 6.96 (3.17 to 10.76) 3.41E-04 IDL free cholesterol 0.10 (1.97 to 2.18) 9.22E-01
IDL phospholipids 9.29 (5.47 to 13.11) 2.18E-06 IDL phospholipids 2.10 (0.04 to 4.16) 4.56E-02
IDL triglycerides 11.42 (7.59 to 15.25) 6.89E-09 IDL triglycerides 7.10 (5.50 to 8.70) 6.03E-18*
LDL triglycerides 6.68 (3.08 to 10.28) 2.89E-04 LDL triglycerides 5.59 (3.92 to 7.26) 6.52E-11*
LDL-3 free cholesterol 8.34 (12.35 to 4.34) 4.83E-05   
LDL-5 triglycerides 6.56 (2.91 to 10.21) 4.46E-04   
Total triglycerides 14.28 (10.60 to 17.96) 6.07E-14 Total triglycerides 11.10 (9.38 to 12.83) 1.90E-35*
VLDL apolipoprotein-B 12.48 (8.81 to 16.15) 4.37E-11   
VLDL cholesterol 10.86 (7.21 to 14.52) 7.85E-09 VLDL cholesterol 8.77 (6.84 to 10.71) 1.22E-18*
VLDL free cholesterol 12.87 (9.20 to 16.54) 1.07E-11   
VLDL phospholipids 13.43 (9.75 to 17.12) 1.76E-12   
VLDL triglycerides 14.91 (11.21 to 18.61) 7.55E-15 VLDL triglycerides 11.39 (9.63 to 13.15) 8.09E-36*
XXL VLDL cholesterol 10.29 (6.41 to 14.16) 2.40E-07 XXL VLDL cholesterol 7.18 (4.65 to 9.71) 3.05E-08*
XXL VLDL free cholesterol 11.68 (7.97 to 15.39) 9.89E-10 XXL VLDL free cholesterol 8.09 (5.60 to 10.58) 2.34E-10*
Continued
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using the assessed genetic instruments linked to blood lipid
levels.
Discussion
Using an untargeted metabolomics platform and a compre-
hensive pathway analysis tool in a large, multiethnic popula-
tion cohort (MESA), we identified a metabolite signature
associated with VAT linked to several putative biological
pathways, including amino acid substrate use/metabolism
and glycolysis/gluconeogenesis. We then replicated our
findings in a separate epidemiological cohort (NEO study)
using targeted metabolomics and found that acetylglycopro-
teins, branched-chain amino acids (isoleucine, leucine, and
valine), glutamine (inversely), and serum triglycerides by 1H
NMR remained associated with VAT, even after adjustment for
established surrogate biomarkers of VAT (BMI, fasting
glucose, waist circumference, and serum triglycerides), sug-
gesting that a single, fasting measurement of metabolites can
provide biological information beyond standard risk markers
of visceral fat. We believe these findings provide insight into
potential mechanisms underpinning VAT metabolism distinct
from generalized obesity (defined by BMI) and help to define a
metabolic signature of visceral adiposity.
A growing number of studies have used targeted metabolic
profiling as a tool for biomarker discovery in obesity, but
studies to date have been composed of relatively small
sample sizes9,10 or histological samples of adipose tissue
alone,12 without targeting plasma-based metabolites that may
be more easily obtained in clinical practice. Menni and
colleagues11 performed targeted metabolomics profiling of
208 plasma metabolites on 2401 women in the United
Kingdom and assessed their relation to VAT measured by dual
x-ray absorptiometry. They also observed associations
between branched-chain amino acids, lactate, and VAT but
did not perform replication studies to confirm their findings.
Thus, one of the strengths of our investigation is the use of 2
well-characterized prospective cohorts, 1 for derivation and 1
for replication, each with dedicated imaging assessments of
VAT, rather than relying on surrogate markers of VAT, such as
anthropometric measurements. Furthermore, we use robust
untargeted NMR-based experiments initially to broadly char-
acterize the metabolic phenotype related to VAT and then
replicate our findings using a targeted NMR approach in a
Table 3. Continued
MESA NEO Study
Metabolite Effect Estimate b (95% CI)
Nominal
P Value Metabolite Effect Estimate b (95% CI)
Nominal P
Value
XXL VLDL phospholipids 15.30 (11.63 to 18.96) 8.45E-16 XXL VLDL phospholipids 9.13 (6.10 to 12.15) 3.81E-09*
XXL VLDL triglycerides 16.17 (12.52 to 19.83) 1.78E-17 XXL VLDL triglycerides 9.37 (4.55 to 14.20) 1.43E-04*
Extralarge VLDL cholesterol 10.23 (6.59 to 13.87) 4.53E-08 Extralarge VLDL cholesterol 7.33 (4.57 to 10.09) 2.03E-07*
Extralarge VLDL free cholesterol 9.82 (6.11 to 13.52) 2.52E-07 Extralarge VLDL free
cholesterol
7.31 (4.75 to 9.87) 2.28E-08*
Extralarge VLDL phospholipids 13.22 (9.56 to 16.88) 2.80E-12 Extralarge VLDL phospholipids 7.67 (4.39 to 10.94) 4.63E-06*
Extralarge VLDL triglycerides 12.92 (9.25 to 16.58) 8.77E-12 Extralarge VLDL triglycerides 9.04 (5.14 to 12.94) 5.87E-06*
Large VLDL cholesterol 10.34 (6.68 to 14.00) 4.00E-08 Large VLDL cholesterol 9.82 (7.84 to 11.79) 4.35E-22*
Large VLDL free cholesterol 10.58 (6.89 to 14.28) 2.51E-08 Large VLDL free cholesterol 9.82 (7.90 to 11.73) 2.50E-23*
Large VLDL phospholipids 11.85 (8.18 to 15.52) 3.75E-10 Large VLDL phospholipids 10.54 (8.55 to 12.53) 9.34E-25*
Large VLDL triglycerides 11.32 (7.65 to 14.98) 2.12E-09 Large VLDL triglycerides 11.24 (9.23 to 13.24) 2.21E-27*
Medium VLDL cholesterol 8.18 (4.60 to 11.75) 8.24E-06 Medium VLDL cholesterol 9.88 (7.95 to 11.81) 2.52E-23*
Medium VLDL free cholesterol 8.04 (4.42 to 11.67) 1.52E-05 Medium VLDL free cholesterol 10.99 (9.16 to 12.82) 3.37E-31*
Medium VLDL phospholipids 9.51 (5.89 to 13.13) 3.16E-07 Medium VLDL phospholipids 11.09 (9.28 to 12.90) 2.52E-32*
Medium VLDL triglycerides 10.08 (6.43 to 13.74) 8.02E-08 Medium VLDL triglycerides 11.39 (9.57 to 13.20) 1.07E-33*
Extrasmall VLDL cholesterol 8.38 (11.94 to 4.82) 4.58E-06   
Extrasmall VLDL phospholipids 12.18 (8.55 to 15.82) 8.37E-11 Extrasmall VLDL phospholipids 4.62 (2.67 to 6.57) 3.53E-06*
Model adjusted for age, sex, race/ethnicity, socioeconomic status, smoking, physical activity, glucose and lipid-lowering medication use, and body mass index. Effect estimate b
represents the difference in VAT area (in cm2) per 1-SD in metabolite intensity (relative units). Lipoprotein particle subclasses range in size from extrasmall to XXL. HDL indicates high-
density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; MESA, Multi-Ethnic Study of Atherosclerosis; NEO, Netherlands Epidemiology in Obesity; VAT,
visceral adipose tissue; VLDL, very-LDL; XXL, very extralarge.
*Metabolites that were significant in the NEO study data set after false-discovery rate correction.
DOI: 10.1161/JAHA.118.010810 Journal of the American Heart Association 9
Metabolic Signature of Visceral Fat Neeland et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
cohort that is well diversified demographically and geograph-
ically from the derivation cohort. All individuals in our study
had assessments of BMI, waist circumference, and fasting
glucose and triglycerides, allowing us to adjust for overall
adiposity, glucose intolerance, and dyslipidemia.
Several limitations of the study merit comment. First, our
findings should be primarily understood within a biological
context; the utility of these metabolites for use in predictive
modeling when added to standard clinical risk scores requires
further study. Second, for MESA, because the metabolites
were measured at a different time point than the abdominal
imaging, we cannot exclude the possibility that metabolite
concentrations might have differed at the follow-up examina-
tion. Different imaging methods were used to estimate VAT in
each cohort; however, the imaging for both cohorts included
the area around the fifth lumbar vertebrae, and multiple
transverse cross-sectional slices were analyzed and averaged
to obtain the final mean VAT value comparable between
Figure 1. Targeted metabolomics pathway analysis in MESA (Multi-Ethnic Study of Atherosclerosis). Each
node represents a separate biochemical pathway. The color of the node corresponds to its location on the y
axis and indicates statistical significance in terms of -log(P) (higher values correspond to lower P values; eg,
red nodes have low P values and yellow nodes have high P values). P values are derived from pathway
enrichment analyses that measure the overall association of a set of metabolites that map to a particular
pathway with the phenotype being examined (visceral adiposity). The size of the node corresponds to its
location on the x axis and indicates to some extent the centrality of the metabolites in the data set for the
represented pathway. This “pathway impact” measure combines theoretic measures to suggest whether
the metabolites are critical connectors within a network as opposed to being more peripheral nodes. The
total pathway impact for all metabolites in any given pathway from the metabolome databases (eg, Kyoto
Encyclopedia of Genes and Genomes and Small Molecule Pathway databases) sum to 1. The pathway
impact reported herein is the cumulative total of pathway impact for all metabolites used for analysis.
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cohorts. Furthermore, prior work showed good agreement
(<3% difference in Bland-Altman analysis) between computed
tomography and MRI for the measurement of VAT.27 Although
the cohorts varied both geographically and demographically,
and metabolites in each cohort were measured using different
algorithms, the replication observed across cohorts despite
these differences in study populations (different amounts of
VAT, different demographics, and different metabolomics
platforms) makes our findings robust. However, it is possible
that differences in ethnicity, diet, or distribution of obesity
between the cohorts could partially explain the variability
observed in metabolite associations in race-stratified
analyses. These differences are likely most important for lipid
metabolites given the known differences in lipid profiles
between white and black individuals.28 Furthermore, these
differences may at least partially explain the observation that
some metabolites found to be significant in MESA are not
replicated in the NEO study. Moreover, we cannot generalize
to other populations not well represented in either cohort in
which alternative metabolite relationships may exist. Because
our study was cross-sectional by design, we cannot comment
on the relationship between temporal changes in metabolite
levels and visceral fat. However, although the Mendelian
randomization analyses did not demonstrate a causal
Figure 2. Associations between metabolites and visceral adipose tissue: correlation of the b coefficients
between the 2 cohort studies. Scatterplot with regression line of b coefficients from each cohort study with
each colored dot representing an individual metabolite. b Coefficients represent the difference in visceral
adipose tissue area (in cm2) per SD metabolite intensity and are from a model adjusted for age, sex, race/
ethnicity, socioeconomic status, smoking, physical activity, glucose and lipid-lowering medication use, and
body mass index. HDL indicates high-density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-
density lipoprotein; MESA, Multi-Ethnic Study of Atherosclerosis; NEO, Netherlands Epidemiology in
Obesity; VLDL, very-LDL.
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relationship between genetic instruments linked to blood lipid
levels and VAT volume, a reverse directionality is more likely
in that excess VAT may cause an atherogenic dyslipidemia. In
line with the study by Xu et al,29 because of the large
differences in GWAS (genome-wide association study) sample
size (n=322 154 for BMI, and n=18 832 for visceral fat), we
cannot exclude that small causal effects of blood lipid
concentrations on visceral fat may have been undetected.
Further Mendelian randomization studies using genetic
instruments linked to VAT will help elucidate the causal
effects of VAT on metabolic traits. Finally, although we
identified several biological pathways using metabolites
associated with VAT, our interpretation of pathways must
remain circumspect and hypothesis generating. In many
instances, the identified metabolites represented substrates
in the pathway rather than products, yielding one-sided
evidence of biological relevance. Furthermore, the level of
metabolomics detail derived with 1H NMR is not sufficient to
yield firm conclusions about the involvement of pathways.
Our findings, which highlight acetylglycoproteins,
branched-chain amino acids, lactate, glutamine (inversely
associated), and an atherogenic dyslipidemic profile (high
triglycerides and VLDL and low HDL) from hundreds of
metabolites assayed, are noteworthy in the context of
experimental and clinical data suggesting that certain
metabolites may be both markers and mediators of adverse
health outcomes related to visceral obesity. For example,
breakdown products of acetylglycoproteins, such as mannose,
are elevated in individuals with insulin resistance30 and
associated with incident type 2 diabetes mellitus and CVD.31
Indeed, we found that total acetylglycoproteins (and mannose
in MESA) were significantly positively associated with VAT and
that they remained associated with VAT even after adjustment
for markers of glycemia and dyslipidemia in the NEO study.
Acetylglycoproteins may perform a variety of cellular func-
tions, including enzymatic catalysis, protein folding, confor-
mation, and stabilization of biological membranes important
for metabolic homeostasis32; perturbation of this highly
Figure 3. Associations between selected metabolites and visceral adiposity, adjusted for important
metabolic phenotypes in the NEO (Netherlands Epidemiology in Obesity) study. Forest plot of associations
between selected metabolites and visceral adipose tissue in the NEO study cohort. Each set of 3 nodes on
the graph corresponds to a different metabolite. The first (red) node in each set represents the difference
with 95% CI in visceral adipose tissue (VAT) area (in cm2) per 1-SD metabolite intensity, adjusted for age,
sex, race/ethnicity, socioeconomic status, smoking, physical activity, glucose and lipid-lowering medication
use, and body mass index. The second (orange) node in each set represents the model additionally adjusted
for fasting plasma glucose level and waist circumference, and the third (blue) node represents the model
additionally adjusted for serum triglyceride level, measured by standard assay.
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regulated system may increase circulating concentrations of
acetylglycoproteins and represent a potential biomarker of
visceral adiposity-related disease risk.
Glutamine, the most abundant free amino acid in human
blood,33 plays a role in a variety of biochemical functions and
was inversely associated with VAT in our study. In prior work,
urinary glutamine was inversely related to higher BMI and
waist circumference in a population-based sample of adults.10
Furthermore, plasma glutamine was inversely correlated with
indexes of obesity and dysglycemia in healthy Japanese
adults,34 and a high plasma glutamine/glutamate ratio was
associated with lower risk of incident diabetes mellitus in the
FHS (Framingham Heart Study).35 In experimental models,
administration of glutamine in mice led to both improved
glucose tolerance and lower blood pressure.35 Therefore, in
the context of these prior studies, our findings may indicate
that visceral obesity reflects a relative “glutamine deficiency,”
representing dysmetabolic, dysfunctional adiposity with
adverse cardiometabolic consequences.
Lactate is a by-product of anaerobic metabolism in cells
when the energy-producing capacity of aerobic metabolism is
exceeded or when oxygen is not available to participate in
cellular respiration. There is substantial evidence, particularly
from animal studies, that hypoxia develops in adipose tissue as
the tissue mass expands, and the reduction in the oxygen
content underlies an inflammatory response.36 In hypoxic
adipose tissue, secretion of multiple inflammation-related
adipokines is upregulated, and there is a switch from oxidative
metabolism to anaerobic glycolysis, with corresponding
increases in lactate production.37 The positive association
between elevated lactate and VAT seen in our study may reflect
the systemic effects of adipose tissue hypoxia, which are more
common in VAT compared with other depots.38 Alternatively,
higher lactate, seen in our study, may reflect abnormal
mitochondrial function.39,40 Metabolic flux studies using
biological tracers have shown that glucose feeds the tricar-
boxylic acid cycle (an integral component of oxidative phos-
phorylation in the electron transport chain in mitochondria) via
circulating lactate and that circulatory turnover flux of lactate is
the highest of all metabolites, exceeding that of glucose in
mice.41 Downregulation of several genes in the electron
transport chain was found in viscerally obese women with
diabetes mellitus and was, in part, mediated by expression of
tumor necrosis factor-a, an important inflammatory cytokine
implicated in the pathogenesis of type 2 diabetes mellitus.42 A
separate study also found that mitochondrial biogenesis and
markers essential to aerobic metabolism were downregulated
in acquired obesity in monozygotic twins.43 Furthermore,
studies of inborn errors of metabolism related to mitochondrial
dysfunction have identified multiple metabolites downstream
of primary mitochondrial lesions, including lactate and sev-
eral amino acids.44,45 Therefore, alterations in whole body
mitochondrial oxidative phosphorylation capacity in multiple
tissues, reflected by metabolomics disturbances, may con-
tribute to a shared pathogenesis of VAT accumulation and
cardiometabolic disease.
Branched-chain amino acids have been consistently linked
to obesity and metabolic disease in recent years. Branched-
chain amino acids are activators of the mammalian target of
rapamycin signaling pathway, and high concentrations of these
amino acids induce mammalian target of rapamycin hyperac-
tivity, leading to impaired pancreatic b cell insulin secretion and
insulin resistance.46 Newgard and colleagues showed, in a rat
model, that a dietary pattern of high-fat consumption with
branched-chain amino acid supplementation led to obesity-
associated insulin resistance via long-term activation of mam-
malian target of rapamycin thatwas reversed by themammalian
target of rapamycin inhibitor, rapamycin.47 They also used
principal components analysis to show that branched-chain
amino acid concentrations can be used to differentiate
metabolic signatures between obese and lean humans. Wang
and colleagues further translated these findings to humans in
the FHS by demonstrating that a branched-chain amino acid
signature was associated with elevated BMI48 and increased
risk of type 2 diabetes mellitus.8 However, they found
considerable overlap in metabolic profiles between BMI, insulin
resistance, and dyslipidemia. Indeed, many studies have found
similar “metabolic profiles” associated with a broad range of
diseases, from diabetes mellitus to CVD, suggesting that
alterations in the metabolic processes reflected by these
biomarkers may be more indicative of generalized metabolic
derangements rather than markers of a specific disease.49 Our
findings may elucidate the reason for this metabolic overlap
because excess visceral adiposity is a fundamental link
between obesity and several adverse cardiometabolic traits.
It is well known that VAT is associated with an atherogenic,
dyslipidemic lipid/lipoprotein profile, including high triglyc-
erides, lowHDL-C,50,51 smaller LDL andHDL particle size, larger
VLDL size, and increased LDL and VLDL particle number.3
Indeed, in our study, HDL-C, larger HDL-related particles, and
plasma apolipoprotein-A1 (a major protein component of HDL
particles in plasma) were inversely associated with VAT,
whereas triglycerides and VLDL-related particles were consis-
tently positively associated with VAT (in both derivation and
replication cohorts). Abnormalities in triglycerides and VLDL
are more closely linked with entities classically related to VAT,
such as the metabolic syndrome, insulin resistance, and the
hypertriglyceridemic waist,52,53 whereas alterations in HDL
metabolism likely relate to atherogenesis through different
mechanisms.54,55 Therefore, our results may reflect multiple
mechanistic pathways through which VAT and lipid/lipopro-
teins interact to influence cardiovascular and metabolic risk.
The ability to identify individuals before the onset of
obesity-related complications is particularly important for
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cardiometabolic diseases because therapies exist that can
slow or prevent end-organ damage over time. Although
anthropometric indexes of obesity (eg, BMI and waist
circumference) are easy to implement clinically, their corre-
lation with direct imaging-based assessments of visceral
adiposity is modest; furthermore, these indexes incorporate
both the abdominal subcutaneous and visceral depots that, as
discussed, are anatomically and functionally distinct. Newer
imaging-based methods offer more sensitivity and specificity
for measuring VAT but have significant drawbacks, limiting
their use in clinical practice. Blood-based metabolic profiling
of VAT using a limited set of important metabolites may
address this implementation gap between recognizing the role
of visceral adiposity in cardiometabolic disease and actually
assessing it clinically. Additional studies examining the
relationship between metabolite signatures and future dia-
betes mellitus and/or cardiovascular events are an exciting
next step in this field. Given that these new analyses would be
more clinically oriented and require rigorous analytical
approaches to evaluate the utility of metabolites in risk
prediction for cardiometabolic events, they are beyond the
scope of the current study.
In conclusion, from a panel of >30 000 metabolomics
features, acetylglycoproteins, branched-chain amino acids,
lactate, glutamine, and markers of atherogenic dyslipidemia
emerged as strong markers of visceral adiposity. A single,
fasting measurement of these metabolites may provide
additional information over standard risk markers of visceral
fat (BMI, fasting glucose, waist circumference, and serum
triglycerides). Further investigation is warranted to determine
whether NMR-based metabolic profiling can improve screen-
ing and detection of visceral adiposity beyond simple
anthropometric measures and the hypertriglyceridemic waist
to help identify appropriate candidates for interventions and
reduce the cardiometabolic complications of visceral obesity.
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Supplemental Methods 
Preparation of samples, including quality controls (QCs)  
The MESA samples were analyzed in two phases as part of EU-funded COMBI-BIO project 
along with samples from two other cohorts: The London Life Sciences Prospective Population1 
(LOLIPOP) and The Rotterdam Study2. Study samples were shipped on dry ice and stored at -
80 C upon arrival until NMR analysis. Two types of QC samples were used to monitor the 
quality of the NMR data. One type (QC1) was a commercially available serum (human serum, 
off the clot, type AB, VWR catalog number BCHRS01049.2-01, VWR International Ltd, UK) 
and the other type (QC2) was prepared by pooling 50 l aliquots of the phase 1 LOLIPOP 
samples. The QCs were aliquoted in 350 μl lots and stored at -80 C. On the day of analysis, both 
QC and study samples were thawed and 300 μl of each sample was mixed with 300 μl of 
phosphate buffer (NaHPO4, 0.075M, pH=7.4, as described previously
3) in Eppendorfs for the 
phase 1 analysis, and in 96 well plates for the phase 2 analysis. After centrifugation (12,000 g at 
4 C for 5 minutes), 550 μl of each sample-buffer mixture was manually transferred into 
SampleJet 5 mm diameter NMR tubes and kept at 4 C until analysis. In phase 1 one QC1 
sample was incorporated in each 96 tube rack. In phase 2, a single QC2 sample was run in each 
96 well plate, and a single QC1 sample was run every two plates. The coefficient of variation 
(CV, %), calculated as the standard deviation/mean concentration per metabolite * 100%, for 
both standard 1D NMR and CPMG acquisitions are listed in the table below. 
 
 MESA 
Metabolite                   Coefficient of variation (%) 
1D NMR 
Acetylglycoproteins 2.08 
Choline 14.26 
Creatinine 2.26 
Glycerol 2.45 
Glyceryl groups of lipids 1.36 
Lactate 5.91 
Mannose 6.55 
Myo-inositol 0.63 
Proline 0.83 
Carr-Purcell-Meiboom-Gill Echo Acquisition (CPMG) 
2-Ketoisovalerate 5.61 
Acetylglycoproteins 4.69 
Alanine 8.55 
Albumin 9.30 
alpha-Glucose 6.75 
Arginine 12.41 
beta-Glucose 12.11 
Choline 9.29 
Citrate 41.50 
Creatinine 13.07 
Ornithine 35.98 
Glutamate 28.45 
Glutamine 9.68 
Glyceryl groups of lipids 18.14 
Isoleucine 6.42 
Lactate 8.49 
Leucine 4.03 
Lysine 17.77 
Mannose 8.47 
Proline 7.19 
Pyroglutamate 12.41 
Valine 12.01 
Metabolites in bold were significant in the NEO dataset after FDR correction 
 
NMR data acquisition 
Serum samples were prepared according to the Bruker standard method.4 A standard 1H NMR 
one-dimensional (1D NMR) spectrum with water suppression (also called the NOESY-presat 
sequence) and a T2-edited spectrum using the CPMG sequence were obtained for each sample. 
The standard 1H NMR spectrum detects the peaks of all proton-containing compounds and as 
such the resultant spectrum comprises sharp peaks for small molecule species, broad bands from 
the lipoproteins and a largely featureless-background from proteins. The CPMG experiment 
exploits the variation in the nuclear spin relaxation times of the large and small molecules to 
reduce the broad signals from the large compounds (proteins and lipoproteins) producing a 
spectrum with a flatter baseline and mainly small molecule metabolite peaks. 1H NMR spectra 
were acquired on a Bruker Ascend spectrometer (Bruker Biospin, Rheinstetten, Germany) 
operating at 600 MHz and equipped with a Bruker Advance III console. 32 scans were collected 
into 131,072 frequency domain points and a line broadening of 0.3 Hz was applied. The spectral 
processing was performed using the software TOPSPIN 3.1 (Bruker Biospin, Rheinstetten, 
Germany). For each spectrum, the free induction decay underwent a zero filling by a factor of 
two and a line broadening of 0.3 Hz producing 128K frequency domain points prior to Fourier 
transformation. The spectra were then automatically phased and baseline corrected and the 
chemical shifts were calibrated to the glucose signal at 5.233 ppm. Spectral data were imported 
into MATLAB (Version 8.3 (R2014a) Mathworks Inc., Natick, MA, USA) for further 
processing. The 1H NMR spectroscopic analysis was completed in six batches corresponding to 
the three cohorts and two 1H NMR experimental phases. The processing workflow to integrate 
the multi-cohort 1H NMR metabolic profiling data has been previously described.5  
 
1H NMR Lipoprotein profiles using Bruker lipoprotein subclass analysis 
The Bruker lipoprotein subclass analysis was applied to the MESA cohort data. The 
quantification of the lipoprotein subclasses is based on the deconvolution of the methyl peak in 
the standard NMR spectrum near 0.89 ppm using a Bruker (Bruker Biospin, Rheinstetten, 
Germany) proprietary procedure adapted from Petersen et al.6 To assess the measurement 
quality, the correlation coefficients between conventional measurements and the Bruker 1H 
NMR-derived values of total HDL, LDL and triglycerides were calculated. Analysis of 105 
lipoprotein subclasses was carried out including different chemical components of IDL (density 
1.006-1.019 kg/L), VLDL (0.950-1.006 kg/L), LDL (density 1.09-1.63 kg/L) and HDL (density 
1.063-1.210 kg/L). The LDL sub-fraction was fractionated into six density classes (LDL-1 
1.019-1.031 kg/L, LDL-2 1.031-1.034 kg/L, LDL-3 1.034-1.037 kg/L, LDL-4 1.037-1.040 kg/L, 
LDL-5 1.040-1.044 kg/L, LDL-6 1.044-1.063 kg/L) and the HDL sub-fraction in four density 
classes (HDL-1 1.063-1.100 kg/L, HDL-2 1.100-1.125 kg/L, HDL-3 1.125-1.175 kg/L, HDL-4 
1.175-1.210 kg/L).6, 7  
 
Metabolite identification 
To help with identification of peaks in the 1H NMR data, reduction using a semi-automatic 
clustering of the full resolution 1H NMR spectrum (30,590 features) was performed using the 
Statistical Recoupling of Variables (SRV).8 The algorithm defines a cluster if 10 or more 
consecutive variables are correlated with each other, with a correlation threshold of r=0.9; 
clusters could also be grouped into a supercluster if the correlation with the neighbouring cluster 
was r=0.9 or above. To optimise the efficiency of SRV, superclusters were generated from the 
aggregation of a maximum of three clusters according to Blaise et al.9 Each cluster was then 
manually checked to improve the groupings and identify peak overlaps. Thus, 132 clusters were 
identified in 1H NMR standard 1D and 157 clusters in CPMG data, each of them corresponding 
to a single peak or a group or peaks.  
 
The chemical shift (in ppm), the coupling constant value (J in Hz), the peak multiplicity (singlet, 
doublet, multiplet) and peak connectivity of the NMR signals of interest were identified using 
1D and 2D (2D JRES, COrrelation SpectroscopY (COSY), TOtal Correlation SpectroscopY 
(TOCSY), Heteronuclear single quantum correlation spectroscopy (HSQC), the Human 
Metabolome Database) NMR experiments and statistical correlation methods (STOCSY 
(Statistical Total Correlation Spectroscopy), STORM (Subset Optimisation by Reference 
Matching)).9-11 This information was then compared with available in-house and publicly 
available databases (Human Metabolome Database12) as well as with published works on human 
serum and plasma metabolite components. The metabolite identities were confirmed by spike-in 
experiments when the chemical standards were available. The level of peak overlap in the 
clusters of interest and the level of confidence in the assignment of the identified metabolites 
were adapted from Sumner et al.13 The metabolite assignment is as follows – 1: Compound 
identified with spiking, 2: Annotated compounds (without chemical reference standards, based 
upon physicochemical properties and/or spectral similarity with public/commercial spectral 
libraries), 3: Putatively characterized compound classes (e.g. based upon characteristic 
physicochemical properties of a chemical class of compounds, or by spectral similarity to known 
compounds of a chemical class) 4: Unknown compounds. a: well-resolved peaks which can be 
differentiated and quantified based upon spectral data. b: Overlapped or low-resolved peaks, 
from which signal differentiation and quantification may be compromised.  
 
Metaboanalyst – a comprehensive tool for metabolomics analysis and interpretation 
The pathway analysis in MetaboAnalyst is a free, web-based tool targeting for metabolomics 
data analysis. It uses the high-quality KEGG metabolic pathways as the backend knowledgebase. 
It integrates many well-established (i.e. univariate analysis, over-representation analysis) 
methods, as well as novel algorithms/concepts (GlobalTest, GlobalAncova, pathway topology 
analysis) into pathway analysis. In addition, MetPA implements a Google-Map style interactive 
visualization system to help users understand their analysis results.  
 
Over-representation analysis is to test if a particular group of compounds is represented more 
than expected by chance within the user uploaded compound list. In the context of pathway 
analysis, we are testing if compounds involved in a particular pathway is enriched compared by 
random hits. The most common methods for such analysis is Fishers' exact test and 
hypergeometric test. Please note, the over-representation analysis only consider the count (i.e. 
the total number of compounds that match a particular pathway) and does not consider the 
magnitude of their concentration changes (not quantitative). So compound that are changed more 
significant will be treated the same as compounds that are less significant.  
Pathway enrichment analysis usually refers to quantitative enrichment analysis directly based on 
the compound concentration values as compared to the compound lists used by over 
representation analysis. It is usually more sensitive than over-representation analysis and has the 
potential to discover "subtle but consistent" changes among compounds within the same 
biological pathway. The program uses GlobalTest and GlobalAncova for pathway enrichment 
analysis when users upload concentration tables. Some important features about these two 
methods include that they support binary, multi-group, as well as continuous phenotypes, and p 
values can be approximated efficiently based on the asymptotic distribution without using 
permutations, which is critical for developing web applications.  
 
The structure of biological pathways represents our knowledge about the complex relationships 
between molecules (activation, inhibition, reaction, etc.). However, neither over-representation 
analysis or pathway enrichment analysis take the pathway structure into consideration when 
determining which pathways are more likely to be involved in the conditions under study. It is 
obvious that changes in the key positions of a network will trigger more severe impact on the 
pathway than changes on marginal or relatively isolated positions. The program uses two well-
established node centrality measures to estimate node importance - betweenness centrality and 
degree centrality. The former focus on node relative to overall pathway structure, while the latter 
focus on immediate local connectivities. 
 
Mendelian Randomization Study of Genetic Traits Linked to Blood Lipid Levels and 
Visceral Adiposity 
We selected uncorrelated genetic instruments previously found to associate with one or more 
lipid traits (high-density lipoprotein cholesterol (HDL-C, n=89), low-density lipoprotein 
cholesterol (LDL-C, n=80), and triglycerides (TG, n=54)) at a genome-wide significant level 
(p<5x10-8) in the largest genome-wide meta-analysis of blood lipid levels to date.14 This study 
included up to 188,577 European-ancestry individuals and estimated the additive effect of each 
genetic variant on blood lipid levels. We subsequently queried a large-scale genome-wide meta-
analysis of ectopic fat depots for each genetic instruments’ effect on visceral adipose tissue 
(VAT) volume.15 This multiethnic meta-analysis included up to 18,332 individuals (18.9% 
African-descent, remainder European-descent) for the analyses on VAT volume and was 
conducted using a weighted z-score based approach, meaning that studies only contributed test 
statistics (z-scores). We therefore approximated beta coefficients and standard errors from the z-
scores, effect allele frequencies, and sample sizes using a previously published method.16 As 
effect allele frequencies were not provided in the publicly available summary statistics of the 
VAT volume analyses (downloaded from the NHLBI GRASP catalog17, Build 2.0.0.0, 
https://grasp.nhlbi.nih.gov/), we utilized 1000 genomes phase 1 version 3 European population-
specific allele frequencies as given in the legend files on the IMPUTE program website 
(https://mathgen.stats.ox.ac.uk/impute/impute.html). Whilst harmonizing the datasets we 
excluded palindromic genetic variants with intermediate minor allele frequencies (above 0.42) to 
avoid effect allele coding errors. Of the thirteen studies contributing to the genome-wide meta-
analysis on VAT volume, four also contributed to the meta-analysis involving blood lipids 
levels. With respect to the larger dataset, up to 3.7% of overlap in participants may therefore 
exist. However, given the strength of the genetic instruments, this overlap is unlikely to 
introduce noticeable bias into the analysis.18  
For each set of genetic instruments (HDL-C, LDL-C, TG) we estimated the causal effect of 
blood lipid level on VAT volume by performing an inverse-variance weighted (IVW) linear 
regression of instrument-outcome associations on instrument-exposure associations, with the 
intercept constrained to zero.19 As the instrument-outcome associations were constructed from z-
scores, these associations and consequently also the causal effect estimators do not have 
interpretable units. However, these estimators can provide insight into the direction of 
association and provide a probability value indicative of the strength of the statistical evidence 
for an association.16 We additionally performed three complementary sensitivity analyses which 
aim to provide asymptotically consistent causal estimates whilst relaxing the requirement of no 
horizontal pleiotropy amongst the genetic variants. First, the MR-Egger approach, of which the 
slope is an estimate of the causal effect and the intercept provides a formal test whether the 
average pleiotropic effect over the variants differs significantly from zero.20 This approach 
assumes that the association of each genetic variant with the exposure is independent of the 
pleiotropic effect of the variant. Secondly, the weighted median estimator, which is consistent 
even when up to 50% of the weight in the analysis comes from invalid instruments.21 Finally, the 
weighted mode-based estimator (MBE), which is consistent if the most common value of 
pleiotropy across the instruments is zero.22 In addition, we provide funnel plots which display the 
causal estimate (i.e. Wald ratio) of each individual genetic variant against their precision. 
Asymmetric plots may be indicative of the presence of directional (i.e. unbalanced) pleiotropy.20 
Instruments were selected and all analyses were performed in R version 3.4.223 using the 
TwoSampleMR R-package which accompanies the MR-base analytical platform.24 
Abbreviation Name Unit 
XL-HDL-P Concentration of very large HDL particles mol/L 
XL-HDL-L Total lipids in very large HDL  mmol/L 
XL-HDL-PL Phospholipids in very large HDL  mmol/L 
XL-HDL-C Total cholesterol in very large HDL  mmol/L 
XL-HDL-CE Cholesterol esters in very large HDL  mmol/L 
XL-HDL-FC Free cholesterol in very large HDL  mmol/L 
XL-HDL-TG Triglycerides in very large HDL  mmol/L 
L-HDL-P Concentration of large HDL particles mol/L 
L-HDL-L Total lipids in large HDL  mmol/L 
L-HDL-PL Phospholipids in large HDL  mmol/L 
L-HDL-C Total cholesterol in large HDL  mmol/L 
L-HDL-CE Cholesterol esters in large HDL  mmol/L 
L-HDL-FC Free cholesterol in large HDL  mmol/L 
L-HDL-TG Triglycerides in large HDL  mmol/L 
M-HDL-P Concentration of medium HDL particles mol/L 
M-HDL-L Total lipids in medium HDL  mmol/L 
M-HDL-PL Phospholipids in medium HDL  mmol/L 
M-HDL-C Total cholesterol in medium HDL  mmol/L 
M-HDL-CE Cholesterol esters in medium HDL  mmol/L 
M-HDL-FC Free cholesterol in medium HDL  mmol/L 
M-HDL-TG Triglycerides in medium HDL  mmol/L 
S-HDL-P Concentration of small HDL particles mol/L 
S-HDL-L Total lipids in small HDL  mmol/L 
S-HDL-PL Phospholipids in small HDL  mmol/L 
S-HDL-C Total cholesterol in small HDL  mmol/L 
S-HDL-CE Cholesterol esters in small HDL  mmol/L 
S-HDL-FC Free cholesterol in small HDL  mmol/L 
S-HDL-TG Triglycerides in small HDL  mmol/L 
XL-HDL-PL_% Phospholipids to total lipids ratio in very large HDL % 
XL-HDL-C_% Total cholesterol to total lipids ratio in very large HDL % 
XL-HDL-CE_% Cholesterol esters to total lipids ratio in very large HDL % 
XL-HDL-FC_% Free cholesterol to total lipids ratio in very large HDL % 
XL-HDL-TG_% Triglycerides to total lipids ratio in very large HDL % 
L-HDL-PL_% Phospholipids to total lipids ratio in large HDL % 
L-HDL-C_% Total cholesterol to total lipids ratio in large HDL % 
L-HDL-CE_% Cholesterol esters to total lipids ratio in large HDL % 
L-HDL-FC_% Free cholesterol to total lipids ratio in large HDL % 
L-HDL-TG_% Triglycerides to total lipids ratio in large HDL % 
M-HDL-PL_% Phospholipids to total lipids ratio in medium HDL % 
M-HDL-C_% Total cholesterol to total lipids ratio in medium HDL % 
M-HDL-CE_% Cholesterol esters to total lipids ratio in medium HDL % 
M-HDL-FC_% Free cholesterol to total lipids ratio in medium HDL % 
M-HDL-TG_% Triglycerides to total lipids ratio in medium HDL % 
S-HDL-PL_% Phospholipids to total lipids ratio in small HDL % 
Table S1. Metabolomics Biomarkers Measured in the NEO Study. 
S-HDL-C_% Total cholesterol to total lipids ratio in small HDL % 
S-HDL-CE_% Cholesterol esters to total lipids ratio in small HDL % 
S-HDL-FC_% Free cholesterol to total lipids ratio in small HDL % 
S-HDL-TG_% Triglycerides to total lipids ratio in small HDL % 
HDL-D Mean diameter for HDL particles nm 
HDL-C Total cholesterol in HDL mmol/L 
HDL2-C Total cholesterol in HDL2 mmol/L 
HDL3-C Total cholesterol in HDL3 mmol/L 
HDL-TG Triglycerides in HDL mmol/L 
   
   
 
IDL-P Concentration of IDL particles mol/L 
IDL-L Total lipids in IDL  mmol/L 
IDL-PL Phospholipids in IDL  mmol/L 
IDL-C Total cholesterol in IDL  mmol/L 
IDL-CE Cholesterol esters in IDL  mmol/L 
IDL-FC Free cholesterol in IDL  mmol/L 
IDL-TG Triglycerides in IDL  mmol/L 
IDL-PL_% Phospholipids to total lipids ratio in IDL % 
IDL-C_% Total cholesterol to total lipids ratio in IDL % 
IDL-CE_% Cholesterol esters to total lipids ratio in IDL % 
IDL-FC_% Free cholesterol to total lipids ratio in IDL % 
IDL-TG_% Triglycerides to total lipids ratio in IDL % 
 
L-LDL-P Concentration of large LDL particles mol/L 
L-LDL-L Total lipids in large LDL  mmol/L 
L-LDL-PL Phospholipids in large LDL  mmol/L 
L-LDL-C Total cholesterol in large LDL  mmol/L 
L-LDL-CE Cholesterol esters in large LDL  mmol/L 
L-LDL-FC Free cholesterol in large LDL  mmol/L 
L-LDL-TG Triglycerides in large LDL  mmol/L 
M-LDL-P Concentration of medium LDL particles mol/L 
M-LDL-L Total lipids in medium LDL  mmol/L 
M-LDL-PL Phospholipids in medium LDL  mmol/L 
M-LDL-C Total cholesterol in medium LDL  mmol/L 
M-LDL-CE Cholesterol esters in medium LDL  mmol/L 
M-LDL-FC Free cholesterol in medium LDL  mmol/L 
M-LDL-TG Triglycerides in medium LDL  mmol/L 
S-LDL-P Concentration of small LDL particles mol/L 
S-LDL-L Total lipids in small LDL  mmol/L 
S-LDL-PL Phospholipids in small LDL  mmol/L 
S-LDL-C Total cholesterol in small LDL  mmol/L 
S-LDL-CE Cholesterol esters in small LDL  mmol/L 
S-LDL-FC Free cholesterol in small LDL  mmol/L 
S-LDL-TG Triglycerides in small LDL  mmol/L 
L-LDL-PL_% Phospholipids to total lipids ratio in large LDL % 
L-LDL-C_% Total cholesterol to total lipids ratio in large LDL % 
L-LDL-CE_% Cholesterol esters to total lipids ratio in large LDL % 
L-LDL-FC_% Free cholesterol to total lipids ratio in large LDL % 
L-LDL-TG_% Triglycerides to total lipids ratio in large LDL % 
M-LDL-PL_% Phospholipids to total lipids ratio in medium LDL % 
M-LDL-C_% Total cholesterol to total lipids ratio in medium LDL % 
M-LDL-CE_% Cholesterol esters to total lipids ratio in medium LDL % 
M-LDL-FC_% Free cholesterol to total lipids ratio in medium LDL % 
M-LDL-TG_% Triglycerides to total lipids ratio in medium LDL % 
S-LDL-PL_% Phospholipids to total lipids ratio in small LDL % 
S-LDL-C_% Total cholesterol to total lipids ratio in small LDL % 
S-LDL-CE_% Cholesterol esters to total lipids ratio in small LDL % 
S-LDL-FC_% Free cholesterol to total lipids ratio in small LDL % 
S-LDL-TG_% Triglycerides to total lipids ratio in small LDL % 
LDL-D Mean diameter for LDL particles nm 
LDL-C Total cholesterol in LDL mmol/L 
LDL-TG Triglycerides in LDL mmol/L 
   
XXL-VLDL-P 
Concentration of chylomicrons and extremely large 
VLDL particles mol/L 
XXL-VLDL-L 
Total lipids in chylomicrons and extremely large VLDL 
particles mmol/L 
XXL-VLDL-PL 
Phospholipids in chylomicrons and extremely large 
VLDL particles mmol/L 
XXL-VLDL-C 
Total cholesterol in chylomicrons and extremely large 
VLDL particles mmol/L 
XXL-VLDL-CE 
Cholesterol esters in chylomicrons and extremely large 
VLDL particles mmol/L 
XXL-VLDL-FC 
Free cholesterol in chylomicrons and extremely large 
VLDL particles mmol/L 
XXL-VLDL-TG 
Triglycerides in chylomicrons and extremely large VLDL 
particles mmol/L 
XL-VLDL-P Concentration of very large VLDL particles mol/L 
XL-VLDL-L Total lipids in very large VLDL  mmol/L 
XL-VLDL-PL Phospholipids in very large VLDL mmol/L 
XL-VLDL-C Total cholesterol in very large VLDL mmol/L 
XL-VLDL-CE Cholesterol esters in very large VLDL mmol/L 
XL-VLDL-FC Free cholesterol in very large VLDL mmol/L 
XL-VLDL-TG Triglycerides in very large VLDL mmol/L 
L-VLDL-P Concentration of large VLDL particles mol/L 
L-VLDL-L Total lipids in large VLDL  mmol/L 
L-VLDL-PL Phospholipids in large VLDL  mmol/L 
L-VLDL-C Total cholesterol in large VLDL  mmol/L 
L-VLDL-CE Cholesterol esters in large VLDL  mmol/L 
L-VLDL-FC Free cholesterol in large VLDL  mmol/L 
L-VLDL-TG Triglycerides in large VLDL mmol/L 
M-VLDL-P Concentration of medium VLDL particles mol/L 
M-VLDL-L Total lipids in medium VLDL mmol/L 
M-VLDL-PL Phospholipids in medium VLDL mmol/L 
M-VLDL-C Total cholesterol in medium VLDL mmol/L 
M-VLDL-CE Cholesterol esters in medium VLDL mmol/L 
M-VLDL-FC Free cholesterol in medium VLDL mmol/L 
M-VLDL-TG Triglycerides in medium VLDL mmol/L 
S-VLDL-P Concentration of small VLDL particles mol/L 
S-VLDL-L Total lipids in small VLDL mmol/L 
S-VLDL-PL Phospholipids in small VLDL mmol/L 
S-VLDL-C Total cholesterol in small VLDL mmol/L 
S-VLDL-CE Cholesterol esters in small VLDL mmol/L 
S-VLDL-FC Free cholesterol in small VLDL mmol/L 
S-VLDL-TG Triglycerides in small VLDL mmol/L 
XS-VLDL-P Concentration of very small VLDL particles mol/L 
XS-VLDL-L Total lipids in very small VLDL  mmol/L 
XS-VLDL-PL Phospholipids in very small VLDL  mmol/L 
XS-VLDL-C Total cholesterol in very small VLDL  mmol/L 
XS-VLDL-CE Cholesterol esters in very small VLDL  mmol/L 
XS-VLDL-FC Free cholesterol in very small VLDL  mmol/L 
XS-VLDL-TG Triglycerides in very small VLDL  mmol/L 
XXL-VLDL-PL_% 
Phospholipids to total lipids ratio in chylomicrons and 
extremely large VLDL % 
XXL-VLDL-C_% 
Total cholesterol to total lipids ratio in chylomicrons and 
extremely large VLDL % 
XXL-VLDL-CE_% 
Cholesterol esters to total lipids ratio in chylomicrons and 
extremely large VLDL % 
XXL-VLDL-FC_% 
Free cholesterol to total lipids ratio in chylomicrons and 
extremely large VLDL % 
XXL-VLDL-TG_% 
Triglycerides to total lipids ratio in chylomicrons and 
extremely large VLDL % 
XL-VLDL-PL_% Phospholipids to total lipids ratio in very large VLDL % 
XL-VLDL-C_% Total cholesterol to total lipids ratio in very large VLDL % 
XL-VLDL-CE_% Cholesterol esters to total lipids ratio in very large VLDL % 
XL-VLDL-FC_% Free cholesterol to total lipids ratio in very large VLDL % 
XL-VLDL-TG_% Triglycerides to total lipids ratio in very large VLDL % 
L-VLDL-PL_% Phospholipids to total lipids ratio in large VLDL % 
L-VLDL-C_% Total cholesterol to total lipids ratio in large VLDL % 
L-VLDL-CE_% Cholesterol esters to total lipids ratio in large VLDL % 
L-VLDL-FC_% Free cholesterol to total lipids ratio in large VLDL % 
L-VLDL-TG_% Triglycerides to total lipids ratio in large VLDL % 
M-VLDL-PL_% Phospholipids to total lipids ratio in medium VLDL % 
M-VLDL-C_% Total cholesterol to total lipids ratio in medium VLDL % 
M-VLDL-CE_% Cholesterol esters to total lipids ratio in medium VLDL % 
M-VLDL-FC_% Free cholesterol to total lipids ratio in medium VLDL % 
M-VLDL-TG_% Triglycerides to total lipids ratio in medium VLDL % 
S-VLDL-PL_% Phospholipids to total lipids ratio in small VLDL % 
S-VLDL-C_% Total cholesterol to total lipids ratio in small VLDL % 
S-VLDL-CE_% Cholesterol esters to total lipids ratio in small VLDL % 
S-VLDL-FC_% Free cholesterol to total lipids ratio in small VLDL % 
S-VLDL-TG_% Triglycerides to total lipids ratio in small VLDL % 
XS-VLDL-PL_% Phospholipids to total lipids ratio in very small VLDL % 
XS-VLDL-C_% Total cholesterol to total lipids ratio in very small VLDL % 
XS-VLDL-CE_% Cholesterol esters to total lipids ratio in very small VLDL % 
XS-VLDL-FC_% Free cholesterol to total lipids ratio in very small VLDL % 
XS-VLDL-TG_% Triglycerides to total lipids ratio in very small VLDL % 
VLDL-D Mean diameter for VLDL particles nm 
VLDL-C Total cholesterol in VLDL mmol/L 
VLDL-TG Triglycerides in VLDL mmol/L 
   
ApoA1 Apolipoprotein A-1 g/L 
ApoB Apolipoprotein B g/L 
ApoB/ApoA1 Ratio of apolipoprotein B to apolipoprotein A-1  
Serum-C Serum total cholesterol mmol/L 
EstC Esterified cholesterol mmol/L 
FreeC Free cholesterol mmol/L 
Remnant-C Remnant cholesterol (non-HDL, non-LDL cholesterol) mmol/L 
Serum-TG Serum total triglycerides mmol/L 
TotPG Total phosphoglycerides mmol/L 
TG/PG Ratio of triglycerides to phosphoglycerides  
PC Phosphatidylcholine and other cholines mmol/L 
SM Sphingomyelins mmol/L 
   
TotCho Total cholines mmol/L 
TotFA Total fatty acids mmol/L 
UnsatDeg Estimated degree of unsaturation  
DHA 22:6, docosahexaenoic acid mmol/L 
LA 18:2, linoleic acid mmol/L 
FAw3 Omega-3 fatty acids mmol/L 
FAw6 Omega-6 fatty acids mmol/L 
PUFA Polyunsaturated fatty acids mmol/L 
MUFA Monounsaturated fatty acids, mainly 16:1 and 18:1 mmol/L 
SFA Saturated fatty acids mmol/L 
DHA/FA Ratio of 22:6 docosahexaenoic acid to total fatty acids % 
LA/FA Ratio of 18:2 linoleic acid to total fatty acids % 
FAw3/FA Ratio of omega-3 fatty acids to total fatty acids % 
FAw6/FA Ratio of omega-6 fatty acids to total fatty acids % 
PUFA/FA Ratio of polyunsaturated fatty acids to total fatty acids % 
MUFA/FA Ratio of monounsaturated fatty acids to total fatty acids % 
SFA/FA Ratio of saturated fatty acids to total fatty acids % 
Glc Glucose mmol/L 
Lac Lactate mmol/L 
Cit Citrate mmol/L 
Ala Alanine mmol/L 
Gln Glutamine mmol/L 
His Histidine mmol/L 
Ile Isoleucine mmol/L 
Leu Leucine mmol/L 
Val Valine mmol/L 
Phe Phenylalanine mmol/L 
Tyr Tyrosine mmol/L 
Ace Acetate mmol/L 
bOHBut 3-hydroxybutyrate mmol/L 
Crea Creatinine mmol/L 
Alb Albumin 
signal 
area 
Gp Glycoprotein acetyls, mainly a1-acid glycoprotein mmol/L 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table of NEO metabolites with median (IQR) concentration values, percent missing, and coefficient of variation 
Metabolite Measured Missing Median 25 percentile 75th percentile Percentage missing CV % (within-subject) Unit 
XXLVLDLP 2058 478 1.06E-10 6.67E-11 1.65E-10 25.151 12.294 mol/L 
XXLVLDLL 2058 478 2.23E-02 1.39E-02 3.51E-02 25.151 12.295 mmol/L 
XXLVLDLPL 2058 478 2.61E-03 1.55E-03 4.21E-03 25.151 12.303 mmol/L 
XXLVLDLC 2058 478 3.22E-03 1.59E-03 5.62E-03 25.151 12.358 mmol/L 
XXLVLDLCE 2058 478 1.68E-03 7.89E-04 3.10E-03 25.151 12.779 mmol/L 
XXLVLDLFC 2058 478 1.53E-03 8.25E-04 2.59E-03 25.151 12.327 mmol/L 
XXLVLDLTG 2058 478 1.66E-02 1.06E-02 2.53E-02 25.151 12.294 mmol/L 
XLVLDLP 2183 353 5.81E-10 3.35E-10 9.58E-10 20.135 12.292 mol/L 
XLVLDLL 2183 353 5.55E-02 3.13E-02 9.21E-02 20.135 12.292 mmol/L 
XLVLDLPL 2183 353 8.43E-03 4.48E-03 1.46E-02 20.135 12.327 mmol/L 
XLVLDLC 2183 353 9.13E-03 4.23E-03 1.61E-02 20.135 12.338 mmol/L 
XLVLDLCE 2183 353 5.11E-03 2.54E-03 9.04E-03 20.135 12.344 mmol/L 
XLVLDLFC 2183 353 3.95E-03 1.64E-03 7.17E-03 20.135 12.641 mmol/L 
XLVLDLTG 2183 353 3.77E-02 2.27E-02 6.20E-02 20.135 12.293 mmol/L 
LVLDLP 2439 97 4.13E-09 2.53E-09 6.45E-09 6.401 8.690 mol/L 
LVLDLL 2439 97 2.34E-01 1.42E-01 3.70E-01 6.401 8.690 mmol/L 
LVLDLPL 2439 97 4.25E-02 2.58E-02 6.66E-02 6.401 8.694 mmol/L 
LVLDLC 2439 97 4.56E-02 2.47E-02 7.60E-02 6.401 8.694 mmol/L 
LVLDLCE 2439 97 2.50E-02 1.45E-02 4.01E-02 6.401 8.697 mmol/L 
LVLDLFC 2439 97 2.06E-02 1.02E-02 3.58E-02 6.401 8.723 mmol/L 
LVLDLTG 2439 97 1.46E-01 9.10E-02 2.26E-01 6.401 8.692 mmol/L 
MVLDLP 2531 5 1.48E-08 1.02E-08 2.11E-08 0.260 0.129 mol/L 
MVLDLL 2531 5 4.92E-01 3.36E-01 6.95E-01 0.260 0.114 mmol/L 
MVLDLPL 2531 5 9.99E-02 6.98E-02 1.39E-01 0.260 0.230 mmol/L 
MVLDLC 2531 5 1.20E-01 8.07E-02 1.73E-01 0.260 0.165 mmol/L 
MVLDLCE 2531 5 6.73E-02 4.67E-02 9.46E-02 0.260 0.287 mmol/L 
MVLDLFC 2531 5 5.38E-02 3.47E-02 7.89E-02 0.260 0.322 mmol/L 
MVLDLTG 2531 5 2.71E-01 1.86E-01 3.87E-01 0.260 0.202 mmol/L 
SVLDLP 2529 7 2.62E-08 2.04E-08 3.27E-08 0.271 0.072 mol/L 
SVLDLL 2529 7 5.05E-01 3.93E-01 6.35E-01 0.271 0.070 mmol/L 
SVLDLPL 2529 7 1.25E-01 1.02E-01 1.52E-01 0.271 0.098 mmol/L 
SVLDLC 2529 7 1.61E-01 1.22E-01 2.07E-01 0.271 0.141 mmol/L 
SVLDLCE 2529 7 9.15E-02 6.51E-02 1.21E-01 0.271 0.217 mmol/L 
SVLDLFC 2529 7 6.99E-02 5.53E-02 8.69E-02 0.271 0.096 mmol/L 
SVLDLTG 2529 7 2.18E-01 1.70E-01 2.83E-01 0.271 0.123 mmol/L 
XSVLDLP 2533 3 3.21E-08 2.67E-08 3.73E-08 0.111 0.086 mol/L 
XSVLDLL 2533 3 4.01E-01 3.33E-01 4.66E-01 0.111 0.094 mmol/L 
XSVLDLPL 2533 3 1.31E-01 1.10E-01 1.53E-01 0.111 0.052 mmol/L 
XSVLDLC 2533 3 1.74E-01 1.38E-01 2.08E-01 0.111 0.185 mmol/L 
XSVLDLCE 2533 3 1.11E-01 8.61E-02 1.35E-01 0.111 0.250 mmol/L 
XSVLDLFC 2533 3 6.25E-02 5.13E-02 7.32E-02 0.111 0.078 mmol/L 
XSVLDLTG 2533 3 9.47E-02 7.96E-02 1.15E-01 0.111 0.099 mmol/L 
IDLP 2536 0 9.20E-08 7.76E-08 1.08E-07 0.000 0.053 mol/L 
IDLL 2536 0 9.32E-01 7.79E-01 1.09E+00 0.000 0.056 mmol/L 
IDLPL 2533 3 2.62E-01 2.23E-01 3.03E-01 0.040 0.047 mmol/L 
IDLC 2533 3 5.72E-01 4.64E-01 6.88E-01 0.040 0.071 mmol/L 
IDLCE 2533 3 4.01E-01 3.24E-01 4.82E-01 0.040 0.083 mmol/L 
IDLFC 2533 3 1.71E-01 1.41E-01 2.03E-01 0.040 0.058 mmol/L 
IDLTG 2533 3 9.86E-02 8.63E-02 1.13E-01 0.040 0.083 mmol/L 
LLDLP 2535 1 1.60E-07 1.34E-07 1.88E-07 0.013 0.032 mol/L 
LLDLL 2535 1 1.14E+00 9.55E-01 1.34E+00 0.013 0.033 mmol/L 
LLDLPL 2535 1 2.91E-01 2.53E-01 3.34E-01 0.013 0.031 mmol/L 
LLDLC 2535 1 7.62E-01 6.27E-01 9.12E-01 0.013 0.036 mmol/L 
LLDLCE 2535 1 5.42E-01 4.42E-01 6.61E-01 0.013 0.039 mmol/L 
LLDLFC 2535 1 2.19E-01 1.85E-01 2.57E-01 0.013 0.046 mmol/L 
LLDLTG 2535 1 8.47E-02 7.26E-02 9.77E-02 0.013 0.089 mmol/L 
MLDLP 2534 2 1.32E-07 1.11E-07 1.57E-07 0.026 0.027 mol/L 
MLDLL 2534 2 6.69E-01 5.63E-01 7.95E-01 0.026 0.018 mmol/L 
MLDLPL 2534 2 1.82E-01 1.59E-01 2.07E-01 0.026 0.032 mmol/L 
MLDLC 2534 2 4.47E-01 3.63E-01 5.42E-01 0.026 0.026 mmol/L 
MLDLCE 2534 2 3.22E-01 2.54E-01 3.99E-01 0.026 0.117 mmol/L 
MLDLFC 2534 2 1.25E-01 1.09E-01 1.43E-01 0.026 0.037 mmol/L 
MLDLTG 2534 2 4.37E-02 3.70E-02 5.07E-02 0.026 0.137 mmol/L 
SLDLP 2534 2 1.54E-07 1.29E-07 1.82E-07 0.026 0.027 mol/L 
SLDLL 2534 2 4.30E-01 3.62E-01 5.09E-01 0.026 0.020 mmol/L 
SLDLPL 2534 2 1.32E-01 1.16E-01 1.49E-01 0.026 0.034 mmol/L 
SLDLC 2534 2 2.71E-01 2.19E-01 3.30E-01 0.026 0.028 mmol/L 
SLDLCE 2534 2 1.98E-01 1.55E-01 2.44E-01 0.026 0.043 mmol/L 
SLDLFC 2534 2 7.38E-02 6.36E-02 8.45E-02 0.026 0.031 mmol/L 
SLDLTG 2534 2 2.74E-02 2.32E-02 3.25E-02 0.026 0.140 mmol/L 
XLHDLP 2419 117 3.51E-07 2.43E-07 4.90E-07 3.494 8.689 mol/L 
XLHDLL 2419 117 3.51E-01 2.42E-01 4.93E-01 3.494 8.689 mmol/L 
XLHDLPL 2419 117 1.85E-01 1.18E-01 2.69E-01 3.494 8.691 mmol/L 
XLHDLC 2419 117 1.53E-01 1.11E-01 2.13E-01 3.494 8.691 mmol/L 
XLHDLCE 2419 117 1.13E-01 8.39E-02 1.55E-01 3.494 8.691 mmol/L 
XLHDLFC 2419 117 4.05E-02 2.61E-02 5.84E-02 3.494 8.698 mmol/L 
XLHDLTG 2419 117 1.22E-02 8.44E-03 1.59E-02 3.494 8.693 mmol/L 
LHDLP 2406 130 1.12E-06 8.02E-07 1.51E-06 3.622 0.093 mol/L 
LHDLL 2406 130 7.02E-01 4.99E-01 9.52E-01 3.622 0.091 mmol/L 
LHDLPL 2406 130 3.58E-01 2.67E-01 4.67E-01 3.622 0.129 mmol/L 
LHDLC 2406 130 3.22E-01 2.12E-01 4.53E-01 3.622 0.137 mmol/L 
LHDLCE 2406 130 2.49E-01 1.67E-01 3.49E-01 3.622 0.142 mmol/L 
LHDLFC 2406 130 7.12E-02 4.51E-02 1.04E-01 3.622 0.510 mmol/L 
LHDLTG 2406 130 2.45E-02 1.88E-02 3.26E-02 3.622 0.347 mmol/L 
MHDLP 2524 12 2.14E-06 1.90E-06 2.38E-06 0.400 0.046 mol/L 
MHDLL 2524 12 9.07E-01 8.02E-01 1.01E+00 0.400 0.049 mmol/L 
MHDLPL 2524 12 4.19E-01 3.72E-01 4.69E-01 0.400 0.041 mmol/L 
MHDLC 2524 12 4.43E-01 3.82E-01 5.00E-01 0.400 0.061 mmol/L 
MHDLCE 2524 12 3.60E-01 3.13E-01 4.07E-01 0.400 0.063 mmol/L 
MHDLFC 2524 12 8.22E-02 6.92E-02 9.47E-02 0.400 0.078 mmol/L 
MHDLTG 2524 12 4.62E-02 4.02E-02 5.33E-02 0.400 0.087 mmol/L 
SHDLP 2531 5 4.95E-06 4.69E-06 5.25E-06 0.074 0.036 mol/L 
SHDLL 2531 5 1.10E+00 1.04E+00 1.16E+00 0.074 0.041 mmol/L 
SHDLPL 2531 5 5.95E-01 5.58E-01 6.34E-01 0.074 0.026 mmol/L 
SHDLC 2531 5 4.51E-01 4.17E-01 4.87E-01 0.074 0.059 mmol/L 
SHDLCE 2531 5 3.44E-01 3.12E-01 3.76E-01 0.074 0.072 mmol/L 
SHDLFC 2531 5 1.08E-01 1.01E-01 1.14E-01 0.074 0.034 mmol/L 
SHDLTG 2531 5 5.02E-02 4.32E-02 5.86E-02 0.074 0.084 mmol/L 
XXLVLDLPLp 2058 478 1.18E+01 1.09E+01 1.23E+01 25.151 0.451 % 
XXLVLDLCp 2058 478 1.45E+01 1.18E+01 1.64E+01 25.151 1.093 % 
XXLVLDLCEp 2058 478 7.88E+00 5.59E+00 9.29E+00 25.151 3.334 % 
XXLVLDLFCp 2058 478 6.90E+00 5.65E+00 7.59E+00 25.151 0.830 % 
XXLVLDLTGp 2058 478 7.39E+01 7.17E+01 7.72E+01 25.151 0.115 % 
XLVLDLPLp 2183 353 1.54E+01 1.40E+01 1.61E+01 20.135 0.900 % 
XLVLDLCp 2183 353 1.65E+01 1.36E+01 1.84E+01 20.135 0.952 % 
XLVLDLCEp 2183 353 9.41E+00 7.88E+00 1.04E+01 20.135 1.027 % 
XLVLDLFCp 2183 353 7.11E+00 5.42E+00 8.09E+00 20.135 2.886 % 
XLVLDLTGp 2183 353 6.82E+01 6.56E+01 7.24E+01 20.135 0.230 % 
LVLDLPLp 2439 97 1.82E+01 1.79E+01 1.86E+01 6.401 0.319 % 
LVLDLCp 2439 97 1.96E+01 1.75E+01 2.10E+01 6.401 0.362 % 
LVLDLCEp 2439 97 1.07E+01 9.80E+00 1.15E+01 6.401 0.399 % 
LVLDLFCp 2439 97 8.88E+00 7.24E+00 9.84E+00 6.401 0.779 % 
LVLDLTGp 2439 97 6.21E+01 6.07E+01 6.43E+01 6.401 0.139 % 
MVLDLPLp 2531 5 2.04E+01 1.99E+01 2.09E+01 0.260 0.239 % 
MVLDLCp 2531 5 2.46E+01 2.28E+01 2.62E+01 0.260 0.176 % 
MVLDLCEp 2531 5 1.35E+01 1.19E+01 1.52E+01 0.260 0.286 % 
MVLDLFCp 2531 5 1.10E+01 1.05E+01 1.14E+01 0.260 0.333 % 
MVLDLTGp 2531 5 5.52E+01 5.32E+01 5.70E+01 0.260 0.123 % 
SVLDLPLp 2529 7 2.45E+01 2.33E+01 2.61E+01 0.271 0.086 % 
SVLDLCp 2529 7 3.17E+01 2.86E+01 3.42E+01 0.271 0.110 % 
SVLDLCEp 2529 7 1.79E+01 1.48E+01 2.04E+01 0.271 0.186 % 
SVLDLFCp 2529 7 1.37E+01 1.34E+01 1.41E+01 0.271 0.099 % 
SVLDLTGp 2529 7 4.38E+01 4.13E+01 4.65E+01 0.271 0.105 % 
XSVLDLPLp 2533 3 3.30E+01 3.13E+01 3.44E+01 0.111 0.069 % 
XSVLDLCp 2533 3 4.32E+01 3.98E+01 4.57E+01 0.111 0.099 % 
XSVLDLCEp 2533 3 2.75E+01 2.45E+01 2.99E+01 0.111 0.161 % 
XSVLDLFCp 2533 3 1.56E+01 1.50E+01 1.61E+01 0.111 0.044 % 
XSVLDLTGp 2533 3 2.38E+01 2.11E+01 2.78E+01 0.111 0.129 % 
IDLPLp 2533 3 2.81E+01 2.75E+01 2.88E+01 0.040 0.033 % 
IDLCp 2533 3 6.15E+01 5.90E+01 6.29E+01 0.040 0.024 % 
IDLCEp 2533 3 4.32E+01 4.10E+01 4.45E+01 0.040 0.036 % 
IDLFCp 2533 3 1.85E+01 1.78E+01 1.91E+01 0.040 0.037 % 
IDLTGp 2533 3 1.05E+01 9.28E+00 1.25E+01 0.040 0.102 % 
LLDLPLp 2535 1 2.56E+01 2.49E+01 2.65E+01 0.013 0.027 % 
LLDLCp 2535 1 6.70E+01 6.53E+01 6.84E+01 0.013 0.015 % 
LLDLCEp 2535 1 4.79E+01 4.58E+01 4.94E+01 0.013 0.022 % 
LLDLFCp 2535 1 1.92E+01 1.87E+01 1.98E+01 0.013 0.035 % 
LLDLTGp 2535 1 7.38E+00 6.51E+00 8.52E+00 0.013 0.088 % 
MLDLPLp 2534 2 2.69E+01 2.57E+01 2.85E+01 0.026 0.029 % 
MLDLCp 2534 2 6.67E+01 6.43E+01 6.85E+01 0.026 0.018 % 
MLDLCEp 2534 2 4.80E+01 4.49E+01 5.04E+01 0.026 0.115 % 
MLDLFCp 2534 2 1.86E+01 1.79E+01 1.95E+01 0.026 0.036 % 
MLDLTGp 2534 2 6.39E+00 5.58E+00 7.48E+00 0.026 0.134 % 
SLDLPLp 2534 2 3.05E+01 2.89E+01 3.24E+01 0.026 0.027 % 
SLDLCp 2534 2 6.33E+01 6.05E+01 6.53E+01 0.026 0.018 % 
SLDLCEp 2534 2 4.61E+01 4.28E+01 4.86E+01 0.026 0.029 % 
SLDLFCp 2534 2 1.71E+01 1.65E+01 1.77E+01 0.026 0.038 % 
SLDLTGp 2534 2 6.33E+00 5.53E+00 7.46E+00 0.026 0.131 % 
XLHDLPLp 2419 117 5.31E+01 4.92E+01 5.55E+01 3.494 0.212 % 
XLHDLCp 2419 117 4.38E+01 4.18E+01 4.65E+01 3.494 0.141 % 
XLHDLCEp 2419 117 3.22E+01 3.02E+01 3.54E+01 3.494 0.141 % 
XLHDLFCp 2419 117 1.16E+01 1.08E+01 1.22E+01 3.494 0.339 % 
XLHDLTGp 2419 117 3.05E+00 2.33E+00 4.53E+00 3.494 0.241 % 
LHDLPLp 2406 130 5.09E+01 4.87E+01 5.35E+01 3.622 0.084 % 
LHDLCp 2406 130 4.58E+01 4.25E+01 4.80E+01 3.622 0.112 % 
LHDLCEp 2406 130 3.56E+01 3.35E+01 3.71E+01 3.622 0.127 % 
LHDLFCp 2406 130 1.02E+01 9.03E+00 1.09E+01 3.622 0.484 % 
LHDLTGp 2406 130 3.46E+00 3.02E+00 4.09E+00 3.622 0.317 % 
MHDLPLp 2524 12 4.63E+01 4.57E+01 4.70E+01 0.400 0.023 % 
MHDLCp 2524 12 4.87E+01 4.71E+01 4.98E+01 0.400 0.024 % 
MHDLCEp 2524 12 3.96E+01 3.83E+01 4.06E+01 0.400 0.027 % 
MHDLFCp 2524 12 9.08E+00 8.64E+00 9.41E+00 0.400 0.058 % 
MHDLTGp 2524 12 5.01E+00 4.29E+00 6.03E+00 0.400 0.099 % 
SHDLPLp 2531 5 5.43E+01 5.26E+01 5.59E+01 0.074 0.019 % 
SHDLCp 2531 5 4.12E+01 3.94E+01 4.29E+01 0.074 0.028 % 
SHDLCEp 2531 5 3.13E+01 2.94E+01 3.33E+01 0.074 0.040 % 
SHDLFCp 2531 5 9.81E+00 9.56E+00 1.01E+01 0.074 0.026 % 
SHDLTGp 2531 5 4.51E+00 3.96E+00 5.28E+00 0.074 0.088 % 
VLDLD 2536 0 3.71E+01 3.62E+01 3.79E+01 0.000 0.011 nm 
LDLD 2536 0 2.35E+01 2.34E+01 2.35E+01 0.000 0.006 nm 
HDLD 2536 0 9.90E+00 9.74E+00 1.01E+01 0.000 0.007 nm 
SerumC 2536 0 4.00E+00 3.48E+00 4.58E+00 0.000 0.027 mmol/L 
VLDLC 2536 0 5.10E-01 3.80E-01 6.81E-01 0.000 0.156 mmol/L 
RemnantC 2536 0 1.10E+00 8.69E-01 1.33E+00 0.000 0.105 mmol/L 
LDLC 2536 0 1.48E+00 1.21E+00 1.78E+00 0.000 0.027 mmol/L 
HDLC 2536 0 1.37E+00 1.15E+00 1.62E+00 0.000 0.047 mmol/L 
HDL2C 2530 6 9.16E-01 7.12E-01 1.15E+00 0.087 0.104 mmol/L 
HDL3C 2536 0 4.58E-01 4.41E-01 4.79E-01 0.000 0.164 mmol/L 
EstC 2525 11 2.80E+00 2.43E+00 3.23E+00 1.069 0.620 mmol/L 
FreeC 2532 4 1.20E+00 1.04E+00 1.36E+00 0.466 1.411 mmol/L 
SerumTG 2536 0 1.15E+00 9.01E-01 1.50E+00 0.000 0.086 mmol/L 
VLDLTG 2536 0 7.62E-01 5.35E-01 1.07E+00 0.000 0.112 mmol/L 
LDLTG 2536 0 1.56E-01 1.34E-01 1.81E-01 0.000 0.105 mmol/L 
HDLTG 2536 0 1.35E-01 1.19E-01 1.51E-01 0.000 0.108 mmol/L 
TotPG 2530 6 1.60E+00 1.38E+00 1.83E+00 0.622 0.853 mmol/L 
TGPG 2495 41 5.31E-01 3.84E-01 7.35E-01 3.568 1.344  
PC 2432 104 1.71E+00 1.51E+00 1.96E+00 6.168 0.879 mmol/L 
SM 2532 4 3.95E-01 3.46E-01 4.47E-01 0.466 0.837 mmol/L 
TotCho 2533 3 1.96E+00 1.72E+00 2.22E+00 0.330 0.853 mmol/L 
ApoA1 2536 0 1.47E+00 1.35E+00 1.61E+00 0.000 0.033 g/L 
ApoB 2535 1 7.80E-01 6.60E-01 8.98E-01 0.017 0.056 g/L 
ApoBApoA1 2535 1 5.25E-01 4.38E-01 6.27E-01 0.017 0.066  
TotFA 2527 9 9.56E+00 8.36E+00 1.09E+01 0.939 1.567 mmol/L 
UnSat 2527 9 1.26E+00 1.21E+00 1.31E+00 0.939 1.158  
DHA 2524 12 1.11E-01 8.34E-02 1.42E-01 1.205 0.879 mmol/L 
LA 2528 8 2.64E+00 2.27E+00 3.00E+00 0.906 1.278 mmol/L 
FAw3 2530 6 3.53E-01 2.87E-01 4.34E-01 0.635 1.872 mmol/L 
FAw6 2530 6 3.26E+00 2.84E+00 3.69E+00 0.635 1.203 mmol/L 
PUFA 2528 8 3.64E+00 3.16E+00 4.10E+00 0.906 1.178 mmol/L 
MUFA 2505 31 2.41E+00 2.06E+00 2.94E+00 2.528 0.892 mmol/L 
SFA 2504 32 3.47E+00 2.98E+00 4.06E+00 2.541 3.446 mmol/L 
DHAFA 2523 13 1.13E+00 9.18E-01 1.42E+00 1.237 1.225 % 
LAFA 2527 9 2.76E+01 2.53E+01 2.98E+01 0.939 1.544 % 
FAw3FA 2527 9 3.62E+00 3.17E+00 4.27E+00 0.939 2.003 % 
FAw6FA 2527 9 3.42E+01 3.20E+01 3.62E+01 0.939 1.319 % 
PUFAFA 2527 9 3.80E+01 3.57E+01 3.99E+01 0.939 1.305 % 
MUFAFA 2503 33 2.57E+01 2.37E+01 2.80E+01 2.800 1.212 % 
SFAFA 2502 34 3.65E+01 3.51E+01 3.78E+01 2.813 2.083 % 
Glc 2535 1 4.17E+00 3.89E+00 4.50E+00 0.033 0.117 mmol/L 
Lac 2536 0 1.04E+00 9.00E-01 1.23E+00 0.000 0.325 mmol/L 
Cit 2536 0 1.50E-01 1.31E-01 1.69E-01 0.000 0.085 mmol/L 
Ala 2536 0 3.43E-01 3.10E-01 3.84E-01 0.000 0.113 mmol/L 
Gln 2536 0 4.76E-01 4.43E-01 5.09E-01 0.000 0.069 mmol/L 
His 2536 0 5.48E-02 5.09E-02 5.90E-02 0.000 0.095 mmol/L 
Ile 2535 1 4.76E-02 3.96E-02 5.75E-02 0.017 0.410 mmol/L 
Leu 2535 1 6.46E-02 5.59E-02 7.45E-02 0.017 0.238 mmol/L 
Val 2536 0 1.52E-01 1.35E-01 1.72E-01 0.000 0.159 mmol/L 
Phe 2536 0 5.25E-02 4.90E-02 5.58E-02 0.000 0.120 mmol/L 
Tyr 2536 0 5.25E-02 4.68E-02 5.86E-02 0.000 0.163 mmol/L 
Ace 2536 0 4.47E-02 3.90E-02 5.31E-02 0.000 0.190 mmol/L 
bOHBut 2532 4 1.18E-01 1.01E-01 1.41E-01 0.176 0.177 mmol/L 
Crea 2536 0 6.33E-02 5.69E-02 7.03E-02 0.000 0.097 mmol/L 
Alb 2536 0 8.57E-02 8.34E-02 8.83E-02 0.000 0.024 signal area 
Gp 2535 1 1.19E+00 1.08E+00 1.31E+00 0.013 0.111 mmol/L 
 
 
 
 
Table S2. Biochemical Pathways Identified from Metabolomics Analysis Associated with Visceral 
Adiposity. 
Pathway Name 
Total 
Pathway 
Metabolites 
Metabolite 
Hits 
Raw p-
value -log(p) Impact 
Aminoacyl-tRNA 
biosynthesis 
75 9 3.39E-10 21.804 0.11268 
Valine, leucine and 
isoleucine 
biosynthesis 
27 4 2.71E-05 10.516 0.12825 
Valine, leucine and 
isoleucine 
degradation 
40 4 0.00013 8.9228 0.03889 
Arginine and proline 
metabolism 
77 5 0.00014 8.9125 0.2709 
Alanine, aspartate 
and glutamate 
metabolism 
24 3 0.00054 7.5224 0.44065 
D-Glutamine and D-
glutamate 
metabolism 
11 2 0.00249 5.9962 0.13904 
Galactose 
metabolism 
41 3 0.00264 5.9355 0.00246 
Pantothenate and 
CoA biosynthesis 
27 2 0.01486 4.2092 0.07366 
Glycolysis or 
Gluconeogenesis 
31 2 0.01936 3.9445 0.01094 
Amino sugar and 
nucleotide sugar 
metabolism 
88 3 0.02215 3.8099 0.01122 
Propanoate 
metabolism 
35 2 0.02437 3.7145 0 
Nitrogen 
metabolism 
39 2 0.02985 3.5116 0 
Fructose and 
mannose 
metabolism 
48 2 0.04378 3.1285 0.03419 
D-Arginine and D-
ornithine 
metabolism 
8 1 0.0552 2.8967 0 
Biotin metabolism 11 1 0.07516 2.5882 0 
Taurine and 
hypotaurine 
metabolism 
20 1 0.13266 2.02 0.03237 
Selenoamino acid 
metabolism 
22 1 0.14497 1.9312 0 
Glycerolipid 
metabolism 
32 1 0.20411 1.5891 0.18847 
Pyruvate 
metabolism 
32 1 0.20411 1.5891 0.13756 
Lysine biosynthesis 32 1 0.20411 1.5891 0.09993 
Glutathione 
metabolism 
38 1 0.23772 1.4367 0.01095 
Glycerophospholipid 
metabolism 
39 1 0.24319 1.4139 0.0212 
Butanoate 
metabolism 
40 1 0.24862 1.3918 0 
Histidine 
metabolism 
44 1 0.26999 1.3094 0.00051 
Lysine degradation 47 1 0.28564 1.253 0.14675 
Glycine, serine and 
threonine 
metabolism 
48 1 0.29078 1.2352 0 
Starch and sucrose 
metabolism 
50 1 0.30097 1.2007 0.03116 
Cysteine and 
methionine 
metabolism 
56 1 0.33071 1.1065 0 
Pyrimidine 
metabolism 
60 1 0.34987 1.0502 0 
Purine metabolism 92 1 0.48561 0.72235 0 
Porphyrin and 
chlorophyll 
metabolism 
104 1 0.52925 0.63629 0 
 
 
 
 
 
 
 
 
 
 
Table S3. Spearman Correlation Coefficients for Body Mass Index, Visceral Adipose Tissue, and Selected Metabolites in 
MESA and NEO Studies. 
 Visceral 
adipose 
tissue 
Acetyl 
glyco-
proteins 
Lactate Isoleucine Leucine Valine Glutamine HDL-
cholesterol 
Triglycerides VLDL-
cholesterol 
Body mass index 0.60 0.22 0.21 0.24 0.13 0.17 -0.21 -0.23 0.25 0.08* 
0.55 0.35 0.22 0.28 0.26 0.27 -0.13 -0.22 0.25 0.18 
Visceral adipose 
tissue 
 0.33 0.37 0.40 0.25 0.24 -0.24 -0.45 0.38 0.26 
0.43 0.33 0.54 0.54 0.45 -0.07* -0.43 0.44 0.36 
Acetylglycoproteins   0.86 0.74 0.59 0.39 -0.44 -0.54 0.79 0.74 
0.37 0.65 0.55 0.28 -0.07* -0.43 0.81 0.70 
Lactate    0.82 0.50 0.35 -0.51 -0.52 0.93 0.80 
0.43 0.39 0.29 -0.11 -0.24 0.38 0.30 
Isoleucine     0.64 0.28 -0.48 -0.53 0.79 0.58 
0.92 0.72 0.04* -0.60 0.76 0.65 
Leucine      0.13 -0.30 -0.37 0.48 0.34 
0.83 0.05* -0.50 0.64 0.55 
Valine       -0.15 -0.28 0.28 0.23 
0.06* -0.39 0.33 0.26 
Glutamine        0.18 -0.59 -0.39 
-0.05* -0.04* -0.04* 
HDL-cholesterol         -0.48 -0.48 
-0.56 -0.47 
Triglycerides          0.77 
0.91 
Top cell: MESA correlations 
Bottom cell: NEO correlations 
MESA: all P<0.0001 except *P=0.006 
NEO: all P<0.0001 except *P<0.05 and **P=0.058 
 
Figure S1. Metabolites Associated with Visceral Adiposity in Sex Stratified Analyses. 
 
 
 
Beige = Lipids, Pink = CPMG, Blue = NOESY. # denotes statistical significance 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. Metabolites Associated with Visceral Adiposity in Race/Ethnicity Stratified 
Analyses. 
 
MESA, sex-stratified 
 
N=569 N=534 
NEO, sex stratified 
 
N=1210 N=1359 
Beige = Lipids, Pink = CPMG, Blue = NOESY. # denotes statistical significance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3. Mendelian Randomization Study of Genetic Traits Linked to Blood Lipid Levels 
with Visceral Adiposity. 
 
MESA, race-stratified 
 NEO, race-stratified 
N=439 N=664 
 
N=2456 N=113 
As shown in the tables below, the IVW estimators did not show statistical evidence of a causal 
effect of these lipid traits on VAT volume. Furthermore, the MR-Egger intercepts were not 
indicative of presence of directional pleiotropy, which is in line with the fairly symmetric funnel 
plots. Results from all sensitivity analyses were consistent with the corresponding IVW causal 
effect estimator, which further underscores the validity of these results.  
We must however acknowledge several limitations of our analyses. These foremost include our 
use of summary statistics from a multiethnic GWAS meta-analysis, due to which we cannot fully 
exclude bias due to population stratification, and that the magnitude of our estimates are not 
interpretable. Finally, using genetic instruments for overall measures of blood lipid traits may not 
be representative for causal effects of the underlying lipoprotein subclasses.  
 
 
 
 
 
 
 
 
 
 
 High-density lipoprotein cholesterol (n=83 instruments) 
Estimator Beta SE p-value 
Inverse Variance Weighted -0.07 0.05 0.17 
MR-Egger intercept -0.002 0.004 0.59 
MR-Egger slope -0.03 0.10 0.78 
Weighted median -0.08 0.07 0.25 
Weighted Mode-Based 
Estimator 
-0.08 0.06 0.24 
 
 
   
 
 
 
 
 
 Low-density lipoprotein cholesterol (n=72 instruments) 
Estimator Beta SE p-value 
Inverse Variance Weighted -0.05 0.05 0.24 
MR-Egger intercept 0.0004 0.004 0.92 
MR-Egger slope -0.06 0.07 0.42 
Weighted median -0.07 0.07 0.27 
 
 
 
 
 
 
Triglycerides (n=53 instruments) 
Estimator Beta SE p-value
Inverse Variance Weighted 0.05 0.06 0.42
MR-Egger intercept -0.004 0.005 0.45
MR-Egger slope 0.11 0.10 0.28
Weighted median 0.07 0.08 0.36
Weighted Mode-Based Estimator 0.11 0.07 0.14
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